Launched in 2013, cruelty-free skincare brand Drunk Elephant has captured the attention of beauty experts, brands, and a strong customer following.

The company, founded by former stay-at-home mom Tiffany Masterson, is one of the fastest-growing skin care brands in the industry. According to Fashionista, this is largely thanks to its philosophy. Masterson is a believer in clean beauty, an ethos thats reflected in Drunk Elephants product line-up. Speaking to how the company came to be, Masterson said, I came up with these criteria: It has to be nontoxic or low-hazard and it has to be bioavailable, meaning able to get into your skin.

As such, all Drunk Elephant products are formulated without what Masterson deemed the Suspicious Six, ingredients that she believed her company could do without: essential oils, silicones, sodium lauryl sulfate aka SLS, drying alcohols, silicones, chemical screens, and fragrances and dyes. When it comes to ingredients, Drunk Elephant goes by the philosophy of If theres any DOUBT, its OUT.

I determined that the six ingredients I wanted to avoid, which I realized were largely there [in competitors products] for marketing, Masterson explained. Silicones make a product feel better; dyes make a product look better; essential oils and fragrance make a product smell better; SLS is a cleansing agent that penetrates your skin and irritates and strips it.

She wanted her brand to be as clean and non-irritating as possible. She even helped formulate the products herself: We went through, ingredient by ingredient, and we swapped out a couple that canceled each other out or that did the same thing, but the resulting ingredient decks were very similar to the ones I first wrote down for every product.

For Masterson, it was a perfect storm of her desire to make a clean beauty brand and evolving consumer shopping habits. Consumer mistrust in companies is on the rise, but for good reason. Last July, Johnson & Johnson was told to pay $4.7 billion to families who claimed that using its talcum powder products caused their ovarian cancer.

While natural and clean beauty are on the rise, Vox points out that the terms are not regulated by the FDA nor the Federal Trade Commission. This means that any company can use the terms for their products and define it as they wish. Clean beauty is still finding favor with consumers its a trend thats been highlighted by Whole Foods Market. People are also becoming concerned over animal ingredients in skincare and makeup, which has helped lead to the rise of vegan beauty, according to The New York Times.

But Drunk Elephants ingredients list shows that Masterson takes her all-natural ethos seriously. In addition to being clean, all products are made in the US.

The company has also resonated with customers Masterson hasnt done any traditional marketing or influencer partnerships. But, she was able to build her brand to the point where she landed in Sephora the TLC Sukari Babyfacial was actually one of the stores top-selling products of 2017.

Drunk Elephant is a cruelty-free brand, but not all products are vegan. The company uses honey in certain formulas. However, it currently offers 12 products formulated without any animal ingredients.

Drunk Elephants A-Passioni Retinol Cream combines vegan retinol with skin-nourishing ingredients like peptides, vitamin F, and plant-based ingredients like passionfruit, apricot, marula and jojoba oils, and kale. This vegan face cream was formulated to diminish the appearance of fine lines and wrinkles and sun damage while evening your skin tone and texture for a younger-looking complexion. Its free from essential oils, silicones, and fragrance.

Check it out here.

Drunk Elephants C-Tango Multivitamin Eye Cream was specially formulated for the sensitive skin around your eyes. This rich, cruelty-free cream features eight peptides, five different kinds of vitamin C and cucumber extract that are said to make skin stronger. According to the company, its rich in antioxidants, ceramides and plant oils that restore and refresh appearance. It can be used in the morning or at night. This cruelty-free formula was named editors choice by Womens Health magazine.

Check it out here.

Described as a retro-style moisturizer, the Lala Retro Whipped Cream is formulated for dull, dry skin. The cream, which has a light, airy texture, is formulated with six African oils that help keep moisture locked in. It contains plantain extract to brighten and sodium hyaluronate crosspolymer that hydrates all day long. Like other Drunk Elephant products, it contains antioxidant-rich ingredients like green tea, which soothes the skin and fights signs of aging. Although its rich, the light airy texture keeps it from feeling heavy on the skin, plus it has a skin friendly pH level of 5.5.

This cream is also a three-time consecutive winner of Allures Readers Choice Awards as well as the 2017 winner of InStyle magazines Readers Choice Beauty Awards.

Check it out here.

Drunk Elephant calls the B-Hydra Intensive Hydration Gel a cool glass of water for your thirsty skin.With a light texture, this gel moisturizer was designed to brighten skintone and improve texture with provitamin B and pineapple ceramide, which helps your skin retain moisture. A blend of watermelon rind, apple, and lentil is said to provide hydration for up to 24 hours. It was designed with molecular size and pH level in mind, resulting in a bio-available moisturizer that keeps your skin looking healthy without irritating it.

Check it out here.

With a breakthrough formula, Protini Polypeptide Cream contains a proprietary lend of peptides, amino acids, and pygmy waterlily that improves skin tone, texture, and firmness. According to Drunk Elephant, the protein-rich formula reduces the appearance of fine lines, wrinkles, and sun damage they say its like adding a shot of plant-based protein to your smoothie. Its ideal for all skin types.

This cruelty-free and vegan moisturizer also won the 2018 Healthy Skin Award from Womens Health and the 2018 Skin Award from Cosmopolitan.

Check it out here.

The Shaba Complex Eye Serum is a satiny moisturizer made to tackle fine lines, wrinkles, and sun damage in the skins delicate undereye area. With ingredients like black tea ferment and copper peptides, this vegan eye serum helps smooth skin and is said to slow down the signs of aging. It also contains edelweiss stem cells and niacinamide, which work to reduce wrinkles. The antioxidant-rich ingredient Co-Q10 helps prevent premature signs of aging and fades age spots.

Check it out here.

The Beste No 9 Jelly Cleanser gets your skin clean without harsh ingredients. A blend of surfactants and emollients gets rid of makeup, excess oil, dirt, and pollution and leaves skin feeling soft when rinsed away. Free from SLS and essential oils, its ideal for all skin types, including sensitive.

This cruelty-free and vegan jelly cleanser was a winner of the 2018 Total Beauty Awards, the 2018 Cosmopolitan Skin Awards, and the 2018 Self Healthy Beauty Awards.

Check it out here.

The three-in-one Juju Bar cleanses, exfoliates, and moisturizes your skin without harsh ingredients. This mild vegan soap bar is formulated with thermal mud and bamboo powder, which help create a lather that helps get rid of dirt and oil. Its also said to minimize the appearance of your pores A superfood blend of acai and goji extracts also help fight the signs of aging while marula oil provides moisture. Its also fragrance-free and wont dry your skin out like conventional bar skin.

Check it out here.

The D-Bronzi Anti-Pollution Sunshine Serum delivers a bronzed look without the long-term consequences of sun damage. This vegan bronzer is made with a chronopeptide that is said to mimic the antioxidant effects of vitamin D, marula oil, and black currant seeds while vitamin F moisturizes and protects. Antioxidant-rich ingredients like raw cocoa powder and white tea also help protect your skin against environmental stressors like pollution while giving your skin a sun-kissed glow.

According to Drunk Elephant, a little bit goes a long way, so it should be mixed with a serum or moisturizer. Its free from fragrance, essential oil, and silicones.

Check it out here.

The T.L.C. Framboos Glycolic Night Serum is a 12 percent AHA/BHA moisturizer that helps refine and resurface skin for a more radiant complexion while reducing the appearance of fine lines, wrinkles, and discoloration. Its said to help boost the performance of other products. This cruelty-free serum is formulated with a blend of glycolic, lactic, tartaric, citric, and salicylic acids plus raspberry extract to deliver chemical exfoliation without harshness. It also contains horse chestnut and white tea to sooth the skin. While AHAs can be sensitizing, plant extracts help keep it balanced.

This vegan and cruelty-free night serum was a winner of the 2018 Shape Editor Pick, the 2018 Real Simple Road Test, and was the product winner of New Beautys Beauty Choice Awards.

Check it out here.

The T.L.C. Sukari Babyfacial is an AHA/BHA, cruelty-free and vegan facial in a bottle. Formulated with every skin type in mind, its made from a blend of glycolic, tartaric, lactic, citric, and salicylic acids that gently exfoliate. Antioxidants like matcha, apple, and milk thistle sooth while sodium hyaluronate crosspolymer and plant-based oils hydrate and nourish. It also contains chickpea flour, which brightens and balances. Niacinamide aka vitamin B3 fights the signs of aging and passion fruit seed oil combats redness. This hydrating facial is said to brighten and tone while minimizing the appearance of pores and fine lines and leaving your skin feeling baby-soft.

A customer favorite, this was a winner of the 2018 Essence Black Beauty Awards, the 2019 Teen Vogue Acne Awards, was featured in Glamour, and it was named on the Into the Gloss Top 25 list.

Check it out here.

Drunk Elephants Virgin Marula Luxury Facial Oil is a luxury moisturizer made from the antioxidants tocopherol (vitamin E), tocotrienol, phenolic compounds, and flavonoids, plus omegas 6 and 9. Described as being like rehab for your skin,this facial oil nourishes your skin to provide a youthful glow. The virgin marula oil featured is extracted from the pip of the fruit and is left pure, without fragrance or added ingredients. This quick-absorbing oil helps reverse the skins of aging, redness, and blotchiness while improving elasticity. Its also naturally anti-microbial and ideal for all skin types.

According to Drunk Elephant, its Virgin Marula Luxury Facial oil is cold-pressed using unheated water extraction, which ensures that the oil stays fresher longer. Its free from fragrance, essential oils, and silicone.

Check it out here.

View post:
The Definitive Guide to All Things Vegan By Drunk Elephant - LIVEKINDLY

Skin Stem Cells Comments Off on The Definitive Guide to All Things Vegan By Drunk Elephant – LIVEKINDLY | December 21st, 2020

Dr. Faye Yin

Dr. Faye Yin

Melanoma is a serious and life-threatening form of cancer that begins in the skin but can spread rapidly if not treated early. We sat down with board-certified oncologist Dr. Faye Yin, an oncologist at Jersey City Medical Center, to learn more about this disease, its causes and risk factors, and why its important to protect yourself from excessive sun exposure even during the cold winter months.

What are the main risk factors for developing melanoma?

Ultraviolet, or UV, light exposure is the major risk factor. Melanoma is associated with both UVB rays, which are present in sunlight, and UVA rays, which are generated by tanning beds. Other risk factors include the presence of moles on the skin. Most are benign, but those with excessive moles should consult a dermatologist, especially if they observe any changes. Often, a mole will be removed as a precautionary measure. Age is also a risk factor; the older the person, the higher the risk. People with fair skin, freckles, and lighter hair are also more susceptible, which is why melanoma is more common in white and light-skinned people. Other risk factors include family history and the presence of a weakened immune system. Those with xeroderma pigmentosum, or XP, a rare genetic disorder, are particularly at risk because the condition affects the ability of skin cells to repair themselves after UV light exposure.

What should people do if they have any of these risk factors?

As with most risk factors impacting health, there are things you can change, and things you cannot. You cant change your skin color or family history, and you cant avoid getting older. But you can limit your exposure to UV rays. A popular catchphrase that I tell my patients, which has been promoted by the American Cancer Society, is Slip, Slop, Slap, and Wrap. Slip on a shirt, slop on some sunscreen, slap on a hat, and wrap on some sunglasses. I also recommend that people avoid using tanning beds and sun lamps. Teaching children about sun safety is especially important, because they tend to spend more time outdoors and can burn more easily. It is also important for people with risk factors to pay closer attention to their skin. Keep an eye out for abnormal moles or other skin features that appear to be unusual or changing over time, and consult a dermatologist if necessary.

Can sunlight still be dangerous during winter?

Yes whether youre skiing or just going for a walk, it is great to enjoy the sun and being outdoors in the winter, but its just as important to protect yourself from excess sun exposure in winter as it is in summer. Harmful ultraviolet rays are present year-round. They can even filter through dark cloud coverage to reach your skin, increasing your risk of melanoma. Some people may experience a bad sunburn on a winter vacation, especially if they ski in high altitudes, because UV rays are usually more intense in higher regions with a thinner atmosphere. When youre outside, any uncovered areas of your body are exposed to UV rays. So, its important to wear sunscreen even in the winter months.

Is smoking a risk factor for developing melanoma, and if so, is it mostly if youre currently smoking (for instance, what if you smoked for years and stopped?)

As an oncologist, every day I tell my patients: dont smoke! Smoking is a contributing factor for many cancers, and I believe that it also affects overall skin health; I can often look at someones skin and tell whether they smoke. That having been said, we dont have evidence that smoking directly contributes to melanoma. But I always encourage patients not to smoke to stay healthy and minimize their cancer risk.

Why does having a weakened immune system count as a risk factor for melanoma?

Having a weakened immune system increases the risk of melanoma and other cancers. I have worked with many patients whose immune systems have been compromised, either by illness or in some cases due to medical treatment for other conditions. For example, immunosuppressive drugs are used after stem cell and organ transplants, to prevent the body from rejecting the transplant. Certain diseases also compromise the immune system, such as HIV. A weakened immune system increases cancer risk for two reasons. First, because the body has less ability to detect and destroy cancer cells. And secondly, because the body is more susceptible to infections that may lead to cancer.

Is gender a risk factor? If so, do we know why?

In the United States, men typically have a higher rate of melanoma than women, though this varies by age. Before age 50, the risk is higher for women, and after age 50, the risk is higher in men. We believe that this discrepancy relates to the fact that men are likely to spend more time in the sun over the course of their lifetimes. I also think that women are more likely to wear sunscreen than men, so this may play a role. In addition, men tend to have thicker skin with less fat beneath it and more collagen, and some research shows that this can make the skin more susceptible to sunlight damage. Also, some studies have shown that estrogen, which is more prevalent in women, can increase resistance to melanoma.

Are older people at higher risk for melanoma?

The risk of melanoma increases as you age. The average age for a melanoma diagnosis is age 65. But melanoma is not uncommon even among those younger than age 30. In fact, it is one of the most common cancers in young adults, especially young women. Melanoma is also more common in younger people whose families have a history of melanoma.

How does having a family history of having melanoma impact someone?

Family history is definitely a melanoma risk factor; the risk is higher among those who have one or more first-degree relatives who have had melanoma. About 10 percent of people diagnosed with melanoma have a family history. Families tend to have shared lifestyle habits, such as more frequent sun exposure, and in addition they typically have similar skin types and share certain genetic characteristics. You cant change your skin color or your genes, but you can change some factors. If you know that you are higher risk, and have a family history, pay close attention to your skin. Avoid excessive sunlight and tanning beds, and consult a dermatologist if you have concerns.

Why is UV light exposure a risk factor?

Numerous studies have shown that sun and UV light exposure is a major melanoma risk factor, especially for children and teens. Research shows that early sun exposure can damage the DNA in skin cells. Melanocytes are the cells that produce melanin, which gives skin its pigmentation, and damaging these cells can start the path to melanoma. Melanoma commonly occurs on the thighs of women, and on the trunks of men, as well as on arms and faces, which are the areas that most often receive chronic sun exposure in young people. In addition to limiting UV light exposure, people should also examine their own skin at least monthly, especially if there are high risk factors. If you see something unusual, such as a large mole or a spot youre not sure about, I will often encourage patients to take a photograph of it. You might not notice small changes over time because you get accustomed to them. But if you take a picture of a spot on your skin and compare it a month or a few months later, and you see a change, you should see a dermatologist.

Go here to see the original:
The facts about the danger of melanoma - The Hudson Reporter

Skin Stem Cells Comments Off on The facts about the danger of melanoma – The Hudson Reporter | December 17th, 2020

Asian beauty woman putting on mask on face. Wearing corona virus prevention masks for long hours are ... [+] creating irritation, skin problems, acne pimples.

Its starts with a seemingly harmless blackhead. Then you notice redness and swelling that will inevitably birth a dreaded pimple. The next thing you know one zit has multiplied to cover almost an entire area of your face along the jawline or chin. Like most skin breakouts, once acne takes over your life, it will often feels like a losing battle.

My bout with acne took over three months of my quarantine life with wounds (okay, maybe scars is a better word for it) that remind me to never again take this skin pandemic lightly. The guesswork was tedious and for weeks seemed futile. There were trial and error attempts, in search of a balancing skincare routine that would clear skin without stripping it off its moisture. This is most important especially for those with combination skin. I even cheated on my trusted dermatologist, only to get a subpar facial that did nothing to improve skins condition. Said facialist, however, offer sound advice: Forego products that will leave your skin oily until the acne has subsided. This will take a while.

Before getting into the meaty details of this war against maskne, lets talk about causes. Maskne is basically acne brought about by wearing face masks for prolonged periods of time. Heat, dirt, sweat and bacteria, when covered by fabrics or other materials used to make face coverings, trigger skin flare ups. Even in cooler temperature, maskne continues to be a bane especially for sensitive skin thats dry and flaky. So yes, the war is far from over, but the good news is it can be won.

A GENTLE AND THOROUGH SKIN CLEANSE is your first step to beating this very frustrating skin condition. I looked far and wide for natural cleansers that would help to control the oil, sebum and dirt. Oil-based cleansers seemed to aggravate the flare up. Bar soaps left skin feeling tight, dry and flaky. Clean facial wash formulations with tea tree oil work wonders as an anti-microbial skin solution. Of the many choices on offer, an all-natural Philippine made Acne Defense Facial Wash from HUMAN NATURE fulfilled its promise of soothing a nasty flare up without drying skin.

Alpyn Beauty's Wild Huckleberry 8-Acid Polishing Peel

Alypn Beauty's Wildhuckleberry 8 Acid Polishing Peel is a multitasking skin treat that works as a ... [+] mask, skin peel and polish.

After a refreshing facial wash, double cleanse with an ultra gentle, multitasking mask, peel and scrub and polish in a jar. ALPYN BEAUTYs Wild Huckleberry 8-Acid Polishing Peel has sold out several times since it launched in Octoberand for good reason. This skin treat harnesses the powers of a natural salicylic, citric, malic, tartaric, glycolic, azelac, ferulic and lactic acids to exfoliate skin and dissolve dead skin cells. Wild crafted huckleberry protects skin barrier, while bamboo power combined with blueberry seed paste effect natural microdermabrasion of skin. This light and delicious skin peel is so gentle you can use is daily, day and night. Ingredients used for this heaven-sent are all sustainably sourced and wild-crafted so you know that it does your skin, soul and planet good. This peel is also ideal for prepping skin before makeup application.

M-61 Power Glow Toner exfoliates away impurities, refine pores, and smoothens skin texture to ... [+] prevent blemishes and quickly improve existing acne

Wipe away deep seated dirt and impurities with M-61s PowerGlow Toner. Formulated with Glycolic Acid and Salicylic Acid, this gentle skin toner exfoliates impurities, refines pores and smoothens skin texture to prevent blemishes and existing acne. Unlike other harsh anti-acne toners that leave skin dry, extra sensitive and flaky, the PowerGlow brings out soft, hydrated and glowing skin. It is also ideal for sensitive skin types that need an extra anti-acne boost.

ZITSTICKA's Press Refresh Sheet Mask combines functional technology and skincare tailored to fight ... [+] acne. It is formulated with salicylic acid, glycolic acid, lactic acid, Niacinamide (to calm) and vitamin A.

Skin flare ups and breakouts in the past have taught me that the first thing to go when pimples take over are heavy creams and moisturizers. As much as we all love a good dose of hydration, war against maskne calls for heavy reinforcements like a hardworking, skin saving face mask. ZITSTICKAs Press Refresh Hydrogel Sheet Mask is a warrior that combines functional technology and skincare tailored to fight acne. It is formulated with salicylic acid, glycolic acid, lactic acid, Niacinamide (to calm) and vitamin A.

Cutting-edge Graphene Technology is used in the sheet mask, which emits infrared rays into the skin, offering enhanced absorption of each ingredient. There are five sheets in every box of Press Refresh. Applied during evenings on alternating days, Press Fresh does a remarkable job in reducing redness and inflammation. By the time the last sheet was used, skin texture had dramatically improved. Pores also appeared smaller. Post acne, Press Refresh is highly recommended as a routine mask for preventing future breakouts. ZITSTICKA is a brand dedicated to creating innovative skin solution that help to fight acne breakouts at all stages.

Peace Out Healing Dots combine Hydrocolloid, Salicylic Acid, Vitamin A and Aloe Vera to clear up ... [+] acne-causing bacteria and reduce redness overnight.

Peace Out Acne Serum is formulated with Salicylic Acid, Niacinamide, Vitamin C & Zinc that work ... [+] together to clear blemishes, prevent them from returning

Maskne is stubborn and often requires a stroke of mad brilliance to beat. PEACE OUT, the leading anti acne skincare brand at Sephora, has changed the way we address breakouts with a full range of innovative skincare solutions. The Acne Healing Dot combines hydrocolloid polymer technology with clean, active ingredients to zap zits. Instead of applying gel or liquid formulas on the surface, PEACE OUT offers fun, stick on skin solutions for hardcore breakouts. I had to try it to believe. To use, simply apply the sticker directly on the affected areas and leave on for a couple of hours. Hydrocolloid dressings absorb moisture and toxins trapped underneath the skins surface, which effectively helps to reduce redness and swelling. Use of this technology also helps to speed up healing of acne. For best results, pair the Healing Dots with PEACE OUTs Acne Serum. Salicylic acid infused with Niacinamide and Vitamin C decongests pores, while reducing the appearance of dark spots and blemishes.

Heraux Molecular Anti-Inflammaging Serum shielding stem cells from the effects of stress and ... [+] promotES their overall youthful function.

Its also essential that you give skin the protective barrier it needs against stressors and irritants. This helps to form a layer that will keep it from inflammation and ultimately, breakouts. HERAUX Molecular Anti Inflammaging Serum uses the first and proprietary Biomimetic Lipid, HX-1, to target inflammaging or aging caused by inflammation. Through the discovery of two stem cell scientists, this breakthrough skincare formulation shields stem cells from the effects of stress and promotes their overall youthful function by modulating the protein that regulates regeneration versus inflammation. The layer has also helped me to protect skin and bring back its radiance and texture.

Ive been using Heraux for a month now, applying a pea-sized amount on thoroughly cleansed skin before getting on with my day. This potent, light serum leaves a matte finish on skin which is brilliant especially when you are paring down on makeup. Pores appear smaller and more importantly, skin barrier is less likely to react to friction or contact with face coverings. After a few weeks of continued use, skin was visibly more youthful and refreshed.

Femmue Lumiere Vital C Serum to help lighten post acne blemishes and dark spots.

Gradually bring back skin hydration into your routine with FEMMUE Ideal Creme Riche

Dull and dry skin with are some of the after effects of a maskne breakout. You can also expect unsightly blemishes and dark spots. To revive clear, smooth and radiant skin, FEMMUEs flower therapy serums and mask did not disappoint. Using modern botanicals, products like Lumiere Vital C Serum and Ideal Cream Riche are skin super healers that restore skins glow and texture. Lumiere is a multi-tasking lightweight formula that works as both an antioxidant and brightening solution. It stimulates collagen production while refining skin surface and lightening dark spots. It is also specially formulated to work beautifully with extra sensitive, acne-prone skin types. For a restorative nighttime skincare routine, pair this serum with FEMMUEs Ideal Crme Riche every other night. Apply a very thin layer all over your face, making sure to tap excess cream with facial tissue. I love to follow with a 10-minute LED Face Mask session just before dozing off.

Scelido Anti Bacterial and Anti Virus Masks are breathable, washable face coverings made with Aero ... [+] Silver fabric and Copper threads.

The best way to keep maskne from taking over your life again is to choose invest in a an antibacterial, breathable face mask. I love a stylish statement masks and have built quite a collection over the months. For long days that will require hours of wear, however, opt for cotton face masks that allow skin to breathe. Infusion of copper and metal ions into the fabric also help to fight off bacteria. SCELIDO Nano Antibacterial and Antivirus Cooling Mask uses ASKIN and Aero Silver fabric, which gives 99.9% antibacterial and UV protection. It is as effective in protecting wearers from viruses as a KF80 but is light, breathable, reusable and effective in preventing acne. Copper threads enhances protection level and seamless ergonomic design (with sizing from XS to Large) allows this facial covering to sit perfectly on skin without causing traction and irritation.

We all look forward to the day when masks and maskne become things of the past. War wounds, otherwise known as acne scars, are slowly beginning to fade. Till then, lessons from this battle remind us that nature truly is the best healer. And as we continue discover the skincare and self care routine that works best for us, any maskne survivor will tell you this: do your research, look at ingredients and dont go into guesswork.

Here is the original post:
A Tried And Tested Guide On How To Win The War Against Maskne - Forbes

Skin Stem Cells Comments Off on A Tried And Tested Guide On How To Win The War Against Maskne – Forbes | December 13th, 2020

This article was originally published here

Lab Invest. 2020 Dec 9. doi: 10.1038/s41374-020-00520-2. Online ahead of print.

ABSTRACT

Disorders involving injury to tissue stem cells that ensure normal tissue homeostasis and repair have potential to show unusually devastating clinical consequences. Acute graft-versus-host disease (aGVHD) is one condition where relatively few cytotoxic immune cells target skin stem cells to produce significant morbidity and mortality. By analogy, SARS-CoV-2 is a vector that initially homes to pulmonary stem cells that preferentially express the ACE2 receptor, thus potentially incurring similarly robust pathological consequences. In older individuals, stem cell number and/or function become depleted due to pathways independent of disease-related injury to these subpopulations. Accordingly, pathologic targeting of stem cells in conditions like aGVHD and COVID-19 infection where these cells are already deficient due to the aging process may have dire consequences in elderly individuals. A hypothesis is herein advanced that, as with aGVHD, lung stem cell targeting is a potential co-factor in explaining age-related severity of COVID-19 infection.

PMID:33299126 | DOI:10.1038/s41374-020-00520-2

Go here to read the rest:
COVID-19 and graft-versus-host disease: a tale of two diseases (and why age matters) - DocWire News

Skin Stem Cells Comments Off on COVID-19 and graft-versus-host disease: a tale of two diseases (and why age matters) – DocWire News | December 10th, 2020

TipRanks

Investing is all about profits, and part of generating profits is knowing when to start the game. The old adage says to buy low and sell high, and while its tempting just to discount cliches like that, theyve passed into common currency because they embody a fundamental truth. Buying low is always a good start in building a portfolio.The trick, however, is recognizing the right stocks to buy low. Prices fall for a reason, and sometimes that reason is fundamental unsoundness. Fortunately, Wall Streets analysts are busy separating the wheat from the chaff among the markets low-priced stocks, and some top stock experts have tagged several equities for big gains. These stocks are trading low now but the reasons are not necessarily bad for investors.Weve used the TipRanks database to pull up the data and reviews on two stocks that are priced low now, but may be primed for gains. Theyve been getting positive reviews, and despite their share depreciation, they hold Buy ratings and show upwards of 60% upside potential.Digital Media Solutions (DMS)We will start with Digital Media Solutions, an adtech company which connects online advertisers with customers through performance-based branding and marketplace solutions. DMS boasts a powerful consumer intelligence database, which it uses to fine-tune customer acquisition campaigns while offering advertisers accountability for the project budget.DMS went public in July of this year, via a merger with a special purpose acquisition company, Leo Holdings. The combination took the DMS name for the ticker, and initiated trading at $10 per share. The stock has been volatile since, and is currently down 27% since it started trading.Digital advertising is a huge and growing sector, worth $100 billion in 2019 and expected to reach $130 billion by the end of next year. DMS has a solid piece of that cash cow, and the Q3 numbers demonstrate that. Quarterly revenue hit a company record, of $82.8 million, which was up 10% sequentially and 44% year-over-year. Of that total revenue, the company saw a gross profit of $25.1 million, for a 30% gross margin. All in all, DMSs first quarter as a publicly traded company showed strong results.Covering the stock for Canaccord is analyst Maria Ripps, who is rated 5 stars by TipRanks, and stands in the top 1% out of more than 7,100 stock analysts. The company saw meaningful volume growth from both new and existing clients, with particular strength from its auto insurance business along with the eCommerce, education, and non-profit verticals We continue to think investors will gradually come to appreciate DMS similarities with other leading digital marketing peers that trade at more premium valuations, and expect multiple expansion over time as the story becomes better understood, Ripps noted.To this end, Ripps rates DMS stock a Buy, and her $15 price target suggests an upside of 106% from the current share price of $7.20. (To watch Ripps track record, click here)Overall, DMS Moderate Buy consensus rating is based on 2 recent reviews, both positive. The stock has an average price target of $14, which indicates a 92% upside potential. (See DMS stock analysis on TipRanks)ViaSat, Inc. (VSAT)From digital advertising we move on to digital networking. ViaSat provides customers with high-speed broadband access through a secure satellite network system. The company serves both military and commercial markets, meeting the growing need for secure communications links.The anti-coronavirus shutdown policies have particularly hard on ViaSat. This may sound counterintuitive, as online networking has been busier than ever, but a large segment of ViaSats business comes from the airlines, and with air travel first grounded and still facing depressed travel volumes, ViaSats shares have yet to recover from their February/March swoon.On a positive note and one that is indicative of the essential nature of secure satellite communications in todays networked economy ViaSat reported $577 million in Q3 contract awards, representing a 29% yoy gain. For the year to date, the company has seen awards totaling $1.9 billion, which is up 5% from this time last year. The third quarter (the companys fiscal Q2) revenues and earnings were somewhat mixed, reflecting both the increase in contract awards and the decline in airline business. Revenues were $554 million, down 6% yoy, but up almost 4% sequentially. EPS was 3 cents per share, beating the predicted 5 cent loss by a wide margin.JPMorgan analyst Philip Cusick writes of ViaSat: [We] believe long-term growth levers remain intact highlighted by record segment backlog of $1.1b We view ViaSat as a satellite innovation leader and believe the companys future ViaSat-3 fleet will accelerate growth in satellite services over the coming years. At the same time, we see a long-term government systems tailwind driven by the companys radio portfolio, mobile broadband, and SATCOM.In line with his bullish comments, Cusick rates VSAT shares an Overweight (i.e. Buy), and his $60 price target implies ~72% upside on the one-year time horizon. (To watch Cusicks track record, click here)Overall, the stock has 5 recent reviews, including 3 Buys and 2 Holds. Shares are priced at $34.14, and the average price target of $55 suggests a 61% upside potential from that level. (See VSAT stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

See more here:
Avenoir Cosmetics Launches Cell Repair Serum - Clinical Strength to Enhance Skin Tone & Minimize Appearance of Sunspots, Blemishes, Discoloration,...

Skin Stem Cells Comments Off on Avenoir Cosmetics Launches Cell Repair Serum – Clinical Strength to Enhance Skin Tone & Minimize Appearance of Sunspots, Blemishes, Discoloration,… | December 10th, 2020

Even while legalization and regulations are in flux throughout the Americas region and around the globe, cannabis beauty is making tremendous progress.

The cannabis market is emerging very, very rapidly around the world, said Shane MacGuill, Senior Head of Nicotine and Cannabis at Euromonitor during a webinar last month reviewing the global cannabis industry across market sectors and showcasing the launch of the market research companys newest Passport Research System focus: cannabis. And he added,the market is currently heavily concentrated in US Canada.

This year2020was the year that both Amway and Avon launched CBD skin care. Avon made the announcement first. In April, as Cosmetics Design reported, the social-selling beauty maker announced plans for a new vegan skin care line that would include a CBD oil. And today, Avon has 3 CBD products in its portfolio: Green Goddess Facial Oil, Veilment CBD Soothing & Nourishing Body Cream, and Veilment CBD Nourishing Body Cream, all of which contain 100mg of CBD. Though as the online product descriptions note, our collection does NOT contain THC. The only high youll get is knowing your skin feels cool, calm and collected.

Amway, as Cosmetics Design reported, announced the launch of its new Artistry Skin Studio product collection in September 2020. And that product line now includes Artistry Studio Zen Daze Ahead Facial Oil +300 mg CBD.

Colgate also got involved in the CBD Beauty market this year. In January the company announced an acquisition deal to buy Hello Products and the following month, Hello launched its CBD product collection, as Cosmetics Design reported. Hello is best known for its oral care products but the brand also makes CBD lip balm, for instance.

Ayuna, a luxury skin care brand out of Spain, just launched the latest limited-edition product in its sought-after Terra collection at the start of November: Terra Bella.

There are no cannabinoids, no THC, no CBD in this new cream. But the Terra Bella face cream is formulated with a remarkable extract derived from cultured Cannabis Sativa stem cells, as Isabel Ramos, Chief Scientific Officer at Ayuna, tells Cosmetics Design.

And the ingredient does something truly extraordinary: it instigates communication between the skin microbiome and the brain, explains Ramos. This topical ingredient is, she says, the first known instance of a skin care input helping and demonstrating that microbiota are acting on [or affecting] how we feel.

As the Ayuna example illustrates, theres a lot more to cannabis beauty than the ever-enchanting CBD. In fact, the entire cannabis plant and a full range of cannabinoid molecules are shaping the future of this buzz-worthy cosmetics and personal care category.

In October, Jennifer Grant, a biomedical engineer turned beauty entrepreneur launched a clean skin care brand called empyri that relies on upcycled cannabis root at its hero ingredient. And not long before that news made headlines here on Cosmetics Design, the biotechnology company behind brands like Bissance and Pipette, announced having successfully scaled production of biotech CBG (one of many cannabinoids naturally occurring in cannabis) for use in skin care product formulations. So while CBD beauty is here to stay, theres much more to Cannabis Sativa and to cannabis beauty than this one molecule. Ready to learn more? Revisit all the top CBD beauty news from 2019 here on CosmeticsDesign.com.

Originally posted here:
CBD: the beauty ingredient trend that can't be stopped - CosmeticsDesign.com USA

Skin Stem Cells Comments Off on CBD: the beauty ingredient trend that can’t be stopped – CosmeticsDesign.com USA | December 10th, 2020

Cell therapies involve the transfer of live cells into a patient to help treat, prevent or potentially cure diseases. One category of cell therapy focuses specifically on the use of stem cells, or cells within the body that have the potential to replace those that are lost through injury or disease. Their versatility and ability to transform allow them to replace problematic or deactivated cells with new, healthy ones is giving patients around the world a second chance at life.Stem cells are found all throughout the human bodyincluding the skin, muscle tissue and even deep inside bone marrow.

Bone marrow, the spongy substance that fills the inner cavities of our bones, is a rich source ofhematopoietic stem cells. These cells are particularly valuable for their ability to develop into all types of blood cells, including white blood cells, red blood cells and platelets. Due to their unique ability,hematopoietic cells can be used to treat certain types of cancer, such as leukemia and lymphomaand have become a staple in the field of regenerative medicine.

Bone marrow aspirate concentrate(BMAC) is a procedure that collects bone marrow from a patient's body and then concentrates it to create the optimal level of stem cells and other crucial growth factors, which can offer a variety of health benefits that traditional surgical methods simply can't offer. Stem cells and their descendants, known as progenitor cells, combined with other bone marrow cells and platelets, have the potential to restore function when injected directly into the patient's damaged tissue. The BMAC procedure is popularly used by physicians who practice orthopedic surgery, pain management and sports medicine. It has been shown torepair tissue damage, preserving function and strengthand in some cases has even beenused as an alternative for more intensive procedures such as joint and hip replacements.

Bone Marrow Aspirate Concentrate is currently being used to:

While there are many bone marrow concentrate technologies currently out on the market, there are none quite like theThermoGenesis PXPSystem. The PXPSystem is an automated, closed system designed for sterile bone marrow separation and concentration. The automated system utilizes highly sensitive sensors to reduce the amount of red blood cells (RBCs) from the initial bone marrow aspirate, providing physicians with a high-quality final product.Red blood cell contaminationis, by far, the biggest issue physicians encounter when using open, non-automated bone marrow processing systems. When high RBC contamination occurs in the bone marrow concentrate, it can impair cell function and diminish the overall effectiveness of the cell treatments. The PXPSystem is specifically designed to eliminate RBCs contamination head-on, boasting aRBC reduction of over 99 percent.

[Link]

The PXPSystem obtains bone marrow concentrates easily, consistently, and reliably, setting itself apart from any other competitors on the market today. The automated nature of the system eliminates factors created by human error and allows for increased precision and control. It gives its user the ability to harvest a precise volume of cell concentrate from the bone marrow aspirate, while producing consistently high mononuclear cells (MNCs) and CD34+ progenitor cell recoveries.

[Link][Link]

Bone marrow aspirate is collected from the patient through a minimally invasive procedure, usually done under local or general anesthesia. After extraction, the aspirate is transferred into the PXP System and processed in a centrifuge to compartmentalize the aspirate into three separate chambers within the Disposable Cartridge - the central processing chamber, the red blood cell depletion chamber and the harvest chamber. The plasma, nucleated cells and RBCs are all sorted by density to create maximum separation of components. The RBCs are then removed and transferred to the depletion chamber, leaving users with a 6 ml harvest of enriched bone marrow concentrate (containing stem cells, platelets, growth factors) ready to be reintroduced into the patient.

The entire process only takes about twenty minutes from the moment the bone marrow aspirate is placed in the system to the point where it can be reinjected. For added convenience, the automated control module provides users with accurate data tracking and serves as a record for the entire process.

The PXPSystem is a tool for physicians looking for a quick, easy and efficient system for processing bone marrow. It is one of the most innovative systems available on the market and our mission is to make it even better. We are currently working with our partners in the field and evolving our products based on their feedback. Based on their response, we've begun designing a stripped-down version of the PXPSystem that requires less accessories and generates a smaller footprint, while still delivering a high-quality final product. Our applications are being developed with the needs of laboratories and physicians in mind, giving them the resources, they need to better serve their patients.

ThermoGenesis Holdings, Inc. (formerly Cesca Therapeutics Inc.), is a pioneer and market leader in the development and commercialization of automated cell processing technologies for the cell and gene therapy fields. We market a full suite of solutions for automated clinical biobanking, COVID-19 testing, point-of-care applications and large-scale cell processing and manufacturing with a special emphasis on the emerging CAR-T immunotherapy market. We are committed to making the world a healthier place by creating innovative solutions for those in need.

To see our full suiteof automated solutions,please visit the shop portion of our website today.

Disclaimer

Thermogenesis Holdings Inc. published this content on 08 December 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 December 2020 18:24:01 UTC

Read the original post:
The Technology Behind Bone Marrow Cellular Processing: The PXP System - marketscreener.com

Skin Stem Cells Comments Off on The Technology Behind Bone Marrow Cellular Processing: The PXP System – marketscreener.com | December 9th, 2020

Dec. 8, 2020 16:00 UTC

DUARTE, Calif.--(BUSINESS WIRE)-- City of Hope doctors participated in research presented at the American Society of Hematology (ASH) virtual meeting, Dec. 5 to 8, that are helping advance the treatment of blood cancers, including one study which demonstrated allogeneic stem cell transplants do have a survival benefit for older adults with myelodysplastic syndromes (MDS) compared with current standard of care.

The study is the largest and most definitive trial to demonstrate the benefits of an allogeneic stem cell transplantation for older adults with MDS, and is just one of numerous studies that City of Hope doctors help lead with the aim of finding more effective treatments of various blood cancers.

This years ASH conference truly showcases City of Hopes leadership in finding more effective treatments for blood cancers, said Stephen J. Forman, M.D., director of City of Hopes Hematologic Malignancies Research Institute. Whether its finding innovative treatments to make it possible for more older adults with cancer to receive stem cell transplants, or pursuing therapies that are more effective with fewer side effects, City of Hope doctors continue to lead innovative research in blood cancers and other hematological malignancies.

City of Hope doctors are leading novel clinical trials for patients with leukemia, lymphoma and other blood cancers.

Multicenter clinical trial led by City of Hope makes stem cell transplant possible for older adults with myelodysplastic syndromes

Allogeneic hematopoietic cell transplantation, or stem cell/bone marrow transplants, for blood cancers that have recurred or are difficult to treat can put the disease into long-term remission and provide a potential cure. The therapy establishes a new, disease-free blood and immune system by transplanting healthy blood stem cells from a donor into a cancer patient after destroying the patients unhealthy bone marrow.

City of Hope and other institutions started this therapy in 1976, primarily for younger patients with blood cancers. The therapy involves using high-dose chemotherapy and/or radiotherapy to make room for a person to receive new stem cells; serious side effects can also occur after transplant. Because of these and other considerations, for many years, older adults with blood cancers have not been considered for transplants.

City of Hope has been leading the way to make transplants possible for more older adults with various cancers.

A new study presented at ASH demonstrates transplants are now a possibility and beneficial for patients with myelodysplastic syndromes (MDS). Approximately 13,000 people in the United States each year are diagnosed with MDS, an umbrella term describing several blood disorders that begin in the bone marrow.

Co-led by City of Hopes Ryotaro Nakamura, M.D., director of City of Hopes Center for Stem Cell Transplantation, the study is the largest and first trial to demonstrate the benefits of an allogeneic stem cell transplantation for older adults with MDS as opposed to the standard of care currently provided to these patients. The multicenter trial for patients aged 50 to 75 with serious MDS compared how long transplant patients survived with those who didnt receive a transplant, as well as disease progression and quality of life. The transplant therapy used reduced-intensity conditioning, which delivers less chemotherapy and radiation before transplant and relies more on the anti-tumor effects of the therapy.

Between 2014 and 2018, the study enrolled 384 participants at 34 cancer centers nationwide. It included 260 patients who were able to find a donor for a transplant, as well as 124 patients who did not find a donor for a transplant.

After three years, nearly 48% of MDS patients who found a donor for transplant had survived compared with about 27% of those patients who didnt have a donor for transplant and received current hypomethylating therapy, a type of chemotherapy that is current standard of care for MDS. Leukemia-free survival which is relevant because myelodysplastic syndrome can develop into leukemia was also greater in transplant recipients after three years nearly 36% compared with about 21% for those who did not have a transplant.

There was a large and significant improvement in survival for patients who had a transplant, Nakamura said. The benefit margin in overall survival was over 20% (21.3%) for patients who had a transplant.

In addition, quality of life was the same for both transplant and nontransplant patients. There were no clinically significant differences when taking such measurements as physical and mental competency scores.

This is an extremely exciting study because it provides evidence that stem cell transplant is highly beneficial for older patients with serious MDS and will likely be practice-changing for this group, Nakamura said. Before, many doctors wouldnt even consider a transplant for this group of patients, but our study demonstrates that these patients should be evaluated for a transplant, which could potentially provide a cure for their disease.

The trial is part of Blood and Marrow Transplant Clinical Trials Network, which was established with support from the National Heart, Lung, and Blood Institute and National Cancer Institute, because of a critical need for multi-institutional clinical trials focused directly on improving survival for patients undergoing hematopoietic cell transplantation.

Updated results from a study of a potential new CAR T cell therapy, liso-cel, for relapsed/refractory chronic lymphocytic leukemia

Patients with relapsed or difficult-to-treat chronic lymphocytic leukemia/small lymphocytic leukemia continue to do well 24 months after receiving lisocabtagene maraleucel (liso-cel) chimeric antigen receptor (CAR) T cells, according to Tanya Siddiqi, M.D., director of City of Hopes Chronic Lymphocytic Leukemia (CLL) Program, which is part of the Toni Stephenson Lymphoma Center. She presented these findings during the 2020 ASH annual meeting virtual conference.

Overall, 23 and 22 patients were evaluated for safety and efficacy in this phase 1 trial, respectively. Their median age was 66 and they had received a median of four prior therapies; all patients had received prior ibrutinib, which is one of the standard of care drugs for CLL.

The overall response rate, or patients whose CLL diminished after liso-cel CAR T cell therapy, was 82%, and 45% of patients also had complete responses, or remissions.

After 15 months of treatment, 53% of patients maintained their responses to the therapy, and six patients continued to be in remission. After 18 months, 50% of patients maintained their response, and there were five remissions. All seven patients who completed the 24-month study maintained their response. Median progression-free survival, or the amount of time the cancer did not worsen during and after treatment, was 18 months.

As early as 30 days after receiving liso-cel, about 75% of 20 patients evaluated for the therapys efficacy had undetectable minimal residual disease (MRD, or no detectable traces of cancer) in the blood and 65% had undetectable MRD in the marrow.

These are remarkable results for a group of patients that prior to this CAR T treatment had no good treatment options if they had already progressed on novel targeted therapies like ibrutinib and venetoclax, Siddiqi said. Liso-cel is providing new hope for CLL patients, and the remissions are also long lasting with few serious side effects.

Because of its safety and effectiveness in clinical trials, liso-cel, which targets the CD19 protein on cancer cells, may soon receive approval from the Food and Drug Administration as a commercial therapy for relapsed or refractory B cell lymphoma. City of Hope is also taking part in the phase 2 trial of liso-cel in CLL patients.

Consolidation treatment with brentuximab vedotin/nivolumab after auto stem cell transplant for relapsed/refractory Hodgkin lymphoma patients leads to 18-month progression free-survival

Patients who have Hodgkin lymphoma that has not been cured by initial treatment will usually receive more chemotherapy and an autologous hematopoietic cell transplant. But even after a stem cell transplant, recurrence of the lymphoma is possible.

This multicenter phase 2 clinical trial, led by City of Hope, examined whether treating patients with brentuximab vedotin (BV), an antibody-based treatment that targets delivery of chemotherapy only to Hodgkin lymphoma cells, and nivolumab, which works by blocking the PD-1 immune checkpoint pathway that Hodgkin lymphoma hijacks to evade the immune system, was safe and effective as consolidation to prevent disease recurrence after transplant in patients with high-risk Hodgkin lymphoma.

Alex Herrera, M.D., assistant professor in City of Hope's Department of Hematology & Hematopoietic Cell Transplantation, discussed 19-month progression-free survival for trial participants, as well as overall survival, safety and response rates during ASH.

Fifty-nine patients were enrolled in the trial. Patients received the consolidation treatment starting a median of 54 days after transplant, and received a median of eight cycles of the therapy. The 19-month progression-free survival in patients was 92%, and overall survival in patients was 98%. Only three patients relapsed after receiving BV and nivolumab consolidation after transplant, and one patient passed away due to PCP pneumonia unrelated to the study treatment.

The most common sides effects related to the treatment were peripheral neuropathy (51%), neutropenia (42%), fatigue (37%) and diarrhea (29%).

Using brentuximab vedotin and nivolumab after transplant is a promising approach for preventing relapse of Hodgkin lymphoma after transplant that merits further study, Herrera said.

City of Hope doctors published research on innovative approaches against graft-versus-host-disease

Historically, a bone marrow/stem cell transplant is more likely to be effective if patients have a donor who is a 100% match, or as close to that as possible. Finding that perfect match is more difficult for African Americans, Latinos, Asian Americans and other ethnic groups as bone marrow donor registries are still trying to increase the number of non-white donors.

Transplant doctors are also looking for ways to make the transplant more effective if a perfect match cant be found; donors who are not a 100% or close match are referred to as mismatched unrelated. One major barrier to these transplants being effective is a condition known as graft-versus-host-disease (GVHD). The condition, which is more common in transplants involving mismatched donors, is caused by donated cells that recognize the recipient's cells as foreign and attack them, damaging the skin, eyes, lungs, liver and digestive tract.

In order to help prevent GVHD, therapies can be given to patients after transplant. A prospective clinical trial at City of Hope examined whether using cyclophosphamide after an infusion of stem cells could prevent GVHD.

Thirty-eight patients were enrolled in the trial, which is the first to examine the use of cyclophosphamide in transplants with a mismatched unrelated donor.

With a median follow-up period of 18 months, 87% of patients had survived, and the majority did not relapse or develop severe GVHD.

During the first 100 days post-transplant, acute GVHD incidence was around 50%; most cases were mild to moderate while severe GVHD was only 15%. A year after transplant, 52% of patients had some form of chronic GVHD, but only 3% had moderate or severe chronic GVHD.

The trial also examined toxicities, infections and immune system recovery after the transplant.

Our study showed that patients who received a transplant from a mismatched unrelated donor using post-transplant cyclophosphamide had a comparable outcome to what we see in matched donor transplants with few cases of serious GVHD cases, said Monzr Al Malki, M.D., associate clinical professor of City of Hopes Department of Hematology & Hematopoietic Cell Transplantation and director of unrelated donor BMT and haploidentical transplant programs. Our data support further development of this therapy in transplant patients who would otherwise have no suitable donors and limited treatment options.

City of Hopes Anthony Stein, M.D., also led a pilot trial that examined whether a new treatment approach may reduce the rate of GVHD in patients with acute myelogenous leukemia (AML) who have received an allogeneic hematopoietic cell transplant. Although a transplant can put AML into remission, GVHD remains the main serious complication after transplant, impacting a patients quality of life and increasing health care costs.

Eighteen patients between the ages of 18 and 60 enrolled in the trial. Each patient received a novel conditioning regimen of total marrow and lymphoid irradiation, which targets a patients marrow and lymph nodes while reducing radiation to other parts of the body, and cyclophosphamide, a therapy that suppresses the immune system. Tacrolimus was also provided to patients.

Radiation was delivered twice daily on the fourth day before transplant and on the day of transplant without chemotherapy. Cyclophosphamide was given to patients on the third and fourth day after transplant.

There were mild to moderate toxicities. Acute GVHD developed in two patients and only one patient developed the most serious GVHD. Five patients developed mild chronic GVHD. Nearly 60% of patients had not developed GVHD or the condition had not worsened after a year.

After a year, all patients had survived, and 83% had not relapsed. After two years, nearly 86% of patients had survived, and the relapse number remained the same.

The therapeutic approach did not interfere with the transplant process as all patients engrafted, or the donors cells started to produce bone marrow and immune cells.

This is welcome news for AML patients who receive an allogeneic transplant and are concerned about developing GVHD, said Stein, associate director of City of Hope's Gehr Family Center for Leukemia Research. Our study demonstrated that using this new combination of therapies is safe and feasible and does not interfere with the engraftment process.

In addition, after a year, patients in this trial were no longer taking immunosuppressive therapy and had an improved quality of life, Stein said. He added that because many of the patients didnt have GVHD, health care costs after a year were also lower than if patients required treatment for the condition.

City of Hope now plans to start a larger phase 2 trial using this treatment approach.

Bispecific antibodies continue to show promise against blood cancers

Mosunetuzumab is a promising new immunotherapy for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL) that recently received breakthrough therapy designation from the Food and Drug Administration. The designation is intended to expedite the development and review of drugs for serious or life-threatening diseases.

Elizabeth Budde, M.D., Ph.D., assistant professor in City of Hope's Department of Hematology & Hematopoietic Cell Transplantation, is leading clinical trials that are showing how well mosunetuzumab works against NHL. At this years ASH, one trial discussed is how the therapy is working for patients with follicular lymphoma.

Mosunetuzumab is a bispecific antibody targeting both CD3 (a protein found on the surface on T cells) and CD20 on the surface of B cells. The therapy redirects T cells to engage and eliminate malignant B cells.

Sixty-two patients, ranging in age from 27 to 85 years old, were enrolled in the trial for follicular lymphoma. They received intravenous doses of mosunetuzumab.

Sixty-eight percent of the patients responded to the therapy, and 50% had a complete response, or went into remission. Consistent complete response rates occurred even in patients with double refractory disease and patients who received prior CAR T cell therapy. Median duration of response was approximately 20 months, and media progression free survival was nearly one year.

Side effects were reported in 60 patients with serious adverse effects in 22 patients. The most frequently reported serious side effects were hypophosphatemia, an electrolyte disorder, and neutropenia, a condition caused by low numbers of white blood cells. Fourteen patients experienced cytokine release syndrome, but none required extensive treatment for it.

Neurological side effects included headache, insomnia and dizziness.

Patients in this trial had high response rates and their disease remained in control for a year, Budde said. This is remarkable because many patients were no longer responding to other therapies.

About City of Hope

City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases. Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hopes translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin and numerous breakthrough cancer drugs are based on technology developed at the institution. A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope has been ranked among the nations Best Hospitals in cancer by U.S. News & World Report for 14 consecutive years. Its main campus is located near Los Angeles, with additional locations throughout Southern California. For more information about City of Hope, follow us on Facebook, Twitter, YouTube or Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201208005458/en/

See the original post:
City of Hope Doctors Present Innovative Therapies to Better Treat Blood Cancers at American Society of Hematology Virtual Conference - BioSpace

Skin Stem Cells Comments Off on City of Hope Doctors Present Innovative Therapies to Better Treat Blood Cancers at American Society of Hematology Virtual Conference – BioSpace | December 9th, 2020

Were all familiar with the usual culprits that lead to skin aging, like not wearing a daily SPF, smoking, lack of hydration, genetics, stress, etc. But in the realm of internal and external factors that can zap your skin of its youthful bounce and glow, theres one important factor that isnt discussed nearly enough: inflammation.

While you might think of this condition only as it relates to a sprained ankle or a particularly aggressive zit, inflammation actually touches our daily lives in a multitude of ways. Its the result of those well-known aging factors (again, like stress and UV rays), but its not always a singular response, like redness or irritation. Says board-certified dermatologist Dr. Joshua Zeichner, Inflammation leads to free-radical damage in the skin, activation of matrix metalloproteinases, and [recruitment of] inflammatory blood cells. Collectively, this leads to damage to skin cells themselves along with destruction of supporting tissue like collagen and elastin. This explains why chronic inflammation can lead to weakening of the skin, premature wrinkling, and sagging.

Brands are starting to take note of how inflammation plays a central role in the aging process, particularly as it relates to the look and feel of our skin, and have dubbed this sequence of events as inflammaging. The beauty industry loves a trendy marketing term, sure, but in this case, there is some real data to back it up.

As Amir Nobakht, MD, MBA, and co-founder of Heraux, explains, Inflammation is supposed to be a temporary response to stress, activating stem cells to regenerate the skin after stress and injuries. However, if inflammation persists, the increased burden on stem cells accelerates the aging process as they are constantly in overdrive. This link between chronic inflammation and aging is referred to as inflammaging.

Together with his business partner Ben Van Handel, PhD, and a stem cell biologist at the University of Southern California, they founded their brand Heraux (which consists of a singular targeted serum with their proprietary molecule, HX-1) to address the signs and symptoms of this detrimental process and modulate the inflammatory pathway in the skin. Full disclosure: This editor has used their serum for as long as its been available, with no plans to stop anytime soon.

So why is this inflammation issue notable if you already know that things like smoking and tanning are bad for you? Well, unfortunately, inflammation is a rather stealthy foe, which can pop up in your skin without any visible indication that its happening. Dr. Nobakht emphasizes, Once [inflammation] is visible on the skin, that indicates a more severe response. This can include redness, rough texture, irritation, and even a burning sensation (think post-sunburn). Again, your skin is experiencing inflammation by its very nature as a barrier between the external and internal in our body. Inflammaging occurs when your skins ability to buffer inflammation is exceeded by the stressors present.

Essentially, the aging process is a slow, silent onethis we knowbut is exacerbated and accelerated by all the choices we make and the inflammatory responses they generate. Once your skin has weathered years and years of this type of inflammation, your defenses are weakened, and those signs of aging, like fine lines, hyperpigmentation, and sagging, inevitably appear.

As bleak as this may sound, there are things you can do to help slow the overall inflammaging progression and prevent premature signs of skin aging. Dr. Zeichner recommends a healthy lifestyle with a balanced diet and plenty of exercise to start, followed by a skin-care routine that incorporates daily sunscreen, gentle cleansers, antioxidant-rich products (think of antioxidants like fire extinguishers that put out inflammation caused by free radicals), a generous helping of moisturizer (particularly at night), and products that promote collagen production like retinoids and bakuchiol.

Advertisement

See original here:
How to Minimize Inflammation and Prevent Your Skin from Inflammaging - Coveteur

Skin Stem Cells Comments Off on How to Minimize Inflammation and Prevent Your Skin from Inflammaging – Coveteur | December 5th, 2020

Aging has implications for a wide range of diseases. Researchers have been looking for ways to halt the aging process for millennia, but such methods remain elusive. Scientists at Harvard Medical School have now offered a glimmer of hope that the aging clock in the eye could be reversedat least in animals.

By reprogramming the expression of three genes, the Harvard team successfully triggered mature nerve cells in mice eyes to adopt a youthful state. The method reversed glaucoma in the mice and reversed age-related vision loss in elderly mice, according to results published in Nature.

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the worlds leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

If further studies prove out the concept, they could pave the way for therapies that employ the same approach to repair damagein other organs and possibly treat age-related diseases in humans, the team said.

The researchers focused on the Yamanaka factors, which are four transcription factorsOct4, Sox2, Klf4 and c-Myc. In a Nobel Prize-winning discovery, Shinya Yamanaka found that the factors can change the epigenomehow genes are turned on or offand can thereby transform mature cellsback to a stem cell-like state. It has been hypothesized that changes to the epigenome drive cell aging, especially a process called DNA methylation, by which methyl groups are tagged onto DNA.

Past researches have tried to use the four Yamanaka factorsto turn back the age clock in living animals, but doing so caused cells to adopt unwanted new identities and induced tumor growth.

RELATED:Restoring eyesight with genetically engineered stem cells

To test whether the approach works in living animals, the scientists used adeno-associated virus to deliver the three genes into the retina of mice with optic nerve injuries. The treatment led to a two-fold increase in the number of retinal ganglion cells, which are neurons responsible for receiving and transmitting visual information. Further analysis showed that the injury accelerated DNA methylation age, while the gene cocktail counteracted that effect.

Next the scientists tested whether the gene therapy could also work in disease settings. In a mouse model of induced glaucomawhich is a leading cause of age-related blindness in peoplethe treatment increased nerve cell electrical activity and the animals visual acuity.

But can the therapy also restore vision loss caused by natural aging? In elderly, 12-month-old mice, the gene therapy also restored ganglion cells electrical activity as well as visual acuity, the team reported.

By comparing cells from the treated micewith retinal ganglion cells from young, 5-month-old mice, the researchers found that mRNA levels of 464 genes were altered during aging, and the gene therapy reversed 90% of those changes. The scientists also noticed reversed patterns of DNA methylation, which suggests that DNA methylation is not just the marker but rather the driver behind aging.

What this tells us is the clock doesn't just represent timeit is time. If you wind the hands of the clock back, time also goes backward, the studys senior author, David Sinclair, explained in a statement.

The study marks the first time that glaucoma-induced vision loss was reversednot just slowedin living animals, according to the team.

RELATED:Reprogrammed skin cells restore sight in mouse models of retinal disease

Other researchers are also studying regenerative approaches to treating eye diseases. A research group at the Centre for Genomic Regulation in Barcelona just showed that by modifying mesenchymal stem cells to express chemokine receptors Ccr5 and Cxcr6, retinal tissue could be saved from degeneration.

The idea of reversing age-related decline in humans by epigenetic reprogramming with a gene therapy is exciting, Sinclair said. The Harvard researchers intend to do more animal work that could allow them to start clinical trials in people with glaucoma in about two years.

Our study demonstrates that it's possible to safely reverse the age of complex tissues such as the retina and restore its youthful biological function, Sinclair said. If affirmed through further studies, these findings could be transformative for the care of age-related vision diseases like glaucoma and to the fields of biology and medical therapeutics for disease at large.

Read more from the original source:
Reversing vision loss by turning back the aging clock - FierceBiotech

Skin Stem Cells Comments Off on Reversing vision loss by turning back the aging clock – FierceBiotech | December 5th, 2020

WASHINGTON, Dec. 4, 2020 /PRNewswire/ --Four studies being presented during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition present opportunities to improve care for patients with a variety of blood disorders. Together, the studies provide support for new clinical approaches such as alternate treatment delivery methods, updated uses for existing therapies, and earlier referrals to specialty care.

"These are very practical trials with real-world implications," said press briefing moderator Lisa Hicks, MD, of St. Michael's Hospital and the University of Toronto. "They address important questions relevant to everyday practice in the clinic."

The first study supports administering the monoclonal antibody daratumumab for multiple myeloma via a quick injection instead of an intravenous infusion, an approach that could save significant time for patients and clinics.

The second study found that, despite being routinely used in practice, the clot stabilizer tranexamic acid does not prevent bleeding when used prophylactically for patients undergoing treatment for blood cancers, although it leaves open the possibility that the drug may be an effective treatment for these patients when bleeding occurs.

The third study reports the drug ruxolitinib can offer relief for patients with chronic graft-versus-host disease (GVHD) after a stem cell transplant, suggesting ruxolitinib is a viable second-line treatment for patients whose symptoms are not fully resolved with corticosteroids.

Finally, the fourth study supports referring older patients with myelodysplastic syndromes to transplant centers for allogeneic hematopoietic cell transplantation, an important shift from current practice that could offer many more patients the potential for a cure.

This press briefing will take place on Friday, December 4, at 9:30 a.m. Pacific time on the ASH annual meeting virtual platform.

Study Bolsters Case for Delivering Daratumumab Subcutaneously for Multiple Myeloma412: Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

A new study suggests the monoclonal antibody daratumumab has similar benefits when delivered via subcutaneous injection as it does when delivered intravenously to individuals with multiple myeloma which persists or recurs after first-line treatments. Patients given subcutaneous daratumumab along with the immunomodulator pomalidomide and the anti-inflammatory steroid dexamethasone were 37% less likely to die or have their disease worsen compared to patients who received pomalidomide and dexamethasone alone in the phase III trial.

"This is an effective combination with a predictable safety profile that allows for the use of subcutaneous daratumumab along with oral pomalidomide and dexamethasone for patients who have received at least one prior line of therapy that included lenalidomide and a proteasome inhibitor," said senior study authorMeletios A. Dimopoulos, MD,of National and Kapodistrian University of Athens in Athens, Greece. "Subcutaneous daratumumab is much easier for the patient and reduces the time they need to spend at the outpatient chemotherapy unit."

The combination of intravenous daratumumab and pomalidomide with dexamethasone has been widely adopted in the U.S. as a second-line therapy for patients whose multiple myeloma does not respond durably to lenalidomide and proteasome inhibitors. However, delivering daratumumab intravenously typically requires patients to spend a full day at the clinic for each infusion. Administering the therapy via a five-minute subcutaneous injection can substantially reduce the burden for patients and clinics, Dr. Dimopoulos said.

The researchers enrolled 304 patients in 12 European countries. Half were randomly assigned to receive daratumumab plus pomalidomide with dexamethasone and half only received pomalidomide with dexamethasone. Patients underwent 28-day treatment cycles until their disease worsened or they experienced unacceptable side effects.

About one-third of patients died during the trial's median follow-up period of about 17 months. The study met its primary endpoint, showing a significantly higher rate of progression-free survival at 12 months among patients receiving the combination therapy. Participants receiving the daratumumab-pomalidomide combination were treated for a median of nearly 12 months, substantially longer than the median treatment duration of less than seven months among those receiving pomalidomide alone.

Patients receiving daratumumab experienced adverse events at a rate consistent with previous studies, raising no new safety concerns. Dr. Dimopoulos said the findings suggest the combination therapy can be a good option for patients who have not experienced lasting benefits from lenalidomide and proteasome inhibitors, particularly those whose cancer is resistant to lenalidomide. He noted that the study suggested a slight trend toward increased survival in the daratumumab arm, but additional follow-up is necessary to assess any survival benefit.

Meletios A. Dimopoulos, MD,National and Kapodistrian University of Athens, will present this study in an oral presentation on Sunday, December 6, at 12:00 noon Pacific time on the ASH annual meeting virtual platform.

Tranexamic Acid Not Found to Prevent Bleeding in Patients with Blood Cancers 2: Effects of Tranexamic Acid Prophylaxis on Bleeding Outcomes in Hematologic Malignancy: The A-TREAT Trial

The clot stabilizer tranexamic acid performed no better than placebo when administered prophylactically to prevent bleeding in patients with blood cancers who also received routine prophylactic platelet transfusions. Researchers cautioned that the study's focus is different from other situations in which tranexamic acid has been found effective, such as its use in treating bleeding related to childbirth, surgery, or inherited blood disorders.

"Clearly patients with low platelet counts and blood cancers have a different kind of bleeding than the bleeding experienced by patients who have suffered some kind of trauma or surgery," said senior study author Terry B. Gernsheimer, MD, of the University of Washington School of Medicine. "Their bleeding likely is due to endothelial damage damage to the lining of blood vessels that tranexamic acid would not treat. To prevent bleeding in these patients, we may need to look at ways to speed the healing of the endothelium that occurs with chemotherapy, radiation, and graft-versus-host disease in patients receiving a transplant."

Between 48% and 70% of patients undergoing treatment for blood cancers experience bleeding complications of World Health Organization grade 2 or higher. Though not life-threatening, grade 2 bleeding for example, a nosebleed lasting more than 30 minutes can be concerning. Bleeding of grade 3 or 4 can be life-threatening and warrant blood transfusions. Most patients undergoing treatment for blood cancers are routinely given platelet transfusions to prevent bleeding, but many continue to experience bleeding episodes, nevertheless.

Tranexamic acid works by slowing the process by which blood clots naturally break down. To determine whether tranexamic acid could help to further reduce bleeding in these patients, the researchers enrolled 327 patients undergoing treatment for blood cancers at three U.S. medical centers. Half were randomly assigned to receive tranexamic acid and half received a placebo, administered either orally or intravenously three times a day until they recovered their platelet count, or for up to 30 days. Researchers regularly followed up with participants to assess bleeding events both in and outside of the hospital.

The results revealed no significant differences among the study groups in terms of the number of bleeding events, the number of red blood cell transfusions, or the number of platelet transfusions patients required during the treatment period and for up to 14 days afterward. Patients receiving tranexamic acid had a significantly higher rate of occlusions in their central venous line (a catheter placed in a large vein commonly used for delivering cancer drugs) which required clearing with a clot-dissolving drug, but there was no difference in the occurrence of clots in patients' veins or arteries.

Dr. Gernsheimer noted that other studies could help elucidate whether the drug may be helpful for specific subgroups of patients with blood cancers or as a treatment for bleeding, rather than as a preventive measure in these patients. It may also be useful to prevent or treat bleeding in patients with other causes of low platelet counts.

Terry B. Gernsheimer, MD, University of Washington School of Medicine, will present this study in a plenary presentation on Sunday, December 6, 2020 at 7:00 a.m. Pacific time on the ASH annual meeting virtual platform.

Researchers Report First Successful Second-Line Treatment for Chronic Graft-Versus-Host Disease77: Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid- Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study

The drug ruxolitinib brought relief from the debilitating effects of chronic graft-versus-host disease (GVHD) at twice the rate of the best available therapy in a phase III trial. The findings represent a major step forward for patients with chronic GVHD that is not resolved by taking corticosteroids, said researchers. There is currently no approved second-line therapy for chronic forms of the disease.

"This is the first multicenter randomized controlled trial for chronic, steroid-refractory or steroid-dependent GVHD that is positive," said senior study authorRobert Zeiser, PhD,of University Medical Center, Freiburg Im Breisgau, Germany. "It shows a significant advantage for ruxolitinib. It is likely that this trial will lead to approval for this indication and change the guidelines for the treatment of this disease."

GVHD is a complication of allogeneic hematopoietic (stem) cell transplantation, a therapy used to treat blood cancers. It occurs when T cells (the graft) received from a donor through the transplant see the patient's healthy cells and tissue (the host) as foreign and start to attack them. Roughly half of patients undergoing a stem cell transplant develop GVHD. About half of these patients are able to resolve their symptoms with a temporary course of corticosteroids, a class of drugs that lower inflammation in the body. The remaining patients either do not respond to steroids, cannot take them, or must take them continuously to stave off symptoms.

Ruxolitinib is designed to block a molecular signal involved in triggering inflammation. A previous trial, REACH2, found that ruxolitinib offered benefits for patients with acute GVHD, a severe form of GVHD with a mortality rate of 80%. The new trial, REACH3, aimed to determine whether the drug could bring similar benefits for the much larger number of patients affected by chronic GVHD. While chronic GVHD is not nearly as deadly as acute GVHD, its symptoms, which include weight loss, skin stiffness, and multiple disabilities, can severely and permanently affect patients' quality of life.

Researchers enrolled 329 patients with moderate-to-severe chronic GVHD. Half were randomly assigned to receive ruxolitinib for six 28-day cycles. The other half received one of nine alternative treatments, representing the best available therapy, at the discretion of their physician. At the end of the six treatment cycles, researchers assessed symptoms of 125 patients who had completed the full course of treatment to which they were assigned.

The trial met its primary endpoint, showing a clear and substantial improvement in the overall response to treatment among patients taking ruxolitinib. Of the 125 patients assessed, 50% of those receiving ruxolitinib had at least some reduction in symptoms, compared to only 25% among those receiving best available therapy. Seven percent of those taking ruxolitinib saw their symptoms resolve completely, compared to only 3% among those receiving best available therapy.

Participants in both arms of the study experienced similar rates of adverse events, which aligned with the health challenges commonly faced by patients with chronic GVHD, suggesting ruxolitinib has an acceptable safety profile in these patients, according to Dr. Zeiser.

Robert Zeiser, PhD, University Medical Center, Freiburg Im Breisgau, Germany, will present this study in an oral presentation on Saturday, December 5, at 8:00 a.m. Pacific time on the ASH annual meeting virtual platform.

Curative Transplant Improves Survival for Older Adults with Myelodysplastic Syndrome75: A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102

Allogeneic hematopoietic cell transplantation nearly doubled the rate of survival among patients 50 to 75 years old with myelodysplastic syndrome (MDS) in a trial conducted by the Blood and Marrow Transplant Clinical Trials Network. Despite being the only known cure for MDS, this therapy is typically only offered to younger patients because its benefits for older adults have not previously been proven. Researchers say the study offers the most definitive evidence to date that this type of stem cell transplantation significantly improves the outlook for older adults who would otherwise face a high likelihood of dying.

"Transplantation has been underutilized, historically, in this patient group," said senior study author Corey Cutler, MD, MPH,of Dana-Farber Cancer Institute. "Based on our findings, all patients should at least be referred to a transplant center so that those who are eligible and who have a suitable donor can undergo transplant and have better survival. It is important to refer these patients early so that the transplant center can work on finding an optimal donor right from the get-go."

Allogeneic hematopoietic (stem) cell transplantation is a process to replace a recipient's stem cells and immune system with cells from a healthy donor. It is the only known method to cure patients with MDS. The Centers for Medicare and Medicaid Services (CMS) covers transplantation for MDS as part of a Coverage with Evidence Development program. CMS approved the design of the trial and is expected to consider the findings when determining future payment policies.

Researchers from the Blood and Marrow Transplant Clinical Trials Network enrolled 384 patients treated for MDS at 34 U.S. medical centers. Patients were referred to transplant centers, which searched for suitable stem cell donors. The 260 patients who were matched with a donor within 90 days were assigned to receive a stem cell transplant; the other 124 patients with no suitable donor received standard supportive care. Participants were followed for roughly three years from their date of enrollment.

Overall survival was much higher in patients assigned to receive a stem cell transplant (47.9%) compared to those who were not (26.6%) at three years from treatment assignment. Leukemia-free survival was also higher in those assigned to receive a transplant (35.8%) than those who were not (20.6%). The researchers observed no significant differences among subgroups and no differences in quality of life between the two study arms.

Dr. Cutler noted that starting the transplantation process as early as possible can increase a patient's chance of finding a suitable donor and successfully proceeding with a transplant.

This study was co-funded by the National, Heart, Lung and Blood Institute (NHLBI) and the National Cancer Institute (NCI), both part of the National Institutes of Health.

Corey Cutler, MD, MPH, Dana-Farber Cancer Institute, will present this study in an oral presentation on Saturday, December 5, at 7:30 a.m. Pacific time on the ASH annual meeting virtual platform.

Additional press briefings will take place throughout the meeting on health disparities, genome editing and cellular therapy, COVID-19, and late-breaking abstracts. For the complete annual meeting program and abstracts, visit http://www.hematology.org/annual-meeting. Follow ASH and #ASH20 on Twitter, Instagram, LinkedIn, and Facebook for the most up-to-date information about the 2020 ASH Annual Meeting.

The American Society of Hematology (ASH) (www.hematology.org) is the world's largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. For more than 60 years, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology. ASH publishes Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field, and Blood Advances (www.bloodadvances.org), an online, peer-reviewed open-access journal.

SOURCE American Society of Hematology

http://www.hematology.org

View post:
Clinical Trials Offer Opportunities to Change Practice to Improve Prevention and Treatment of Blood Disorders - PRNewswire

Skin Stem Cells Comments Off on Clinical Trials Offer Opportunities to Change Practice to Improve Prevention and Treatment of Blood Disorders – PRNewswire | December 5th, 2020

Stem cells are biological cells which have the ability to distinguish into specialized cells, which are capable of cell division through mitosis. Amniotic fluid stem cells are a collective mixture of stem cells obtained from amniotic tissues and fluid. Amniotic fluid is clear, slightly yellowish liquid which surrounds the fetus during pregnancy and is discarded as medical waste during caesarean section deliveries. Amniotic fluid is a source of valuable biological material which includes stem cells which can be potentially used in cell therapy and regenerative therapies. Amniotic fluid stem cells can be developed into a different type of tissues such as cartilage, skin, cardiac nerves, bone, and muscles. Amniotic fluid stem cells are able to find the damaged joint caused by rheumatoid arthritis and differentiate tissues which are damaged. Medical conditions where no drug is able to lessen the symptoms and begin the healing process are the major target for amniotic fluid stem cell therapy. Amniotic fluid stem cells therapy is a solution to those patients who do not want to undergo surgery. Amniotic fluid has a high concentration of stem cells, cytokines, proteins and other important components. Amniotic fluid stem cell therapy is safe and effective treatment which contain growth factor helps to stimulate tissue growth, naturally reduce inflammation. Amniotic fluid also contains hyaluronic acid which acts as a lubricant and promotes cartilage growth.

Get Free Sample Copy With Impact Analysis Of COVID-19 Of Market Report @https://www.persistencemarketresearch.com/samples/23101

With increasing technological advancement in the healthcare, amniotic fluid stem cell therapy has more advantage over the other therapy. Amniotic fluid stem cell therapy eliminates the chances of surgery and organs are regenerated, without causing any damage. These are some of the factors driving the growth of amniotic fluid stem cell therapy market over the forecast period. Increasing prevalence of chronic diseases which can be treated with the amniotic fluid stem cell therapy propel the market growth for amniotic fluid stem cell therapy, globally. Increasing funding by the government in research and development of stem cell therapy may drive the amniotic fluid stem cell therapy market growth. But, high procedure cost, difficulties in collecting the amniotic fluid and lack of reimbursement policies hinder the growth of amniotic fluid stem cell therapy market.

The global amniotic fluid stem cell therapy market is segmented on basis of treatment, application, end user and geography:

You Can Buy This PMR Healthcare Report From Here @https://www.persistencemarketresearch.com/checkout/23101

Rapid technological advancement in healthcare, and favorable results of the amniotic fluid stem cells therapy will increase the market for amniotic fluid stem cell therapy over the forecast period. Increasing public-private investment for stem cells in managing disease and improving healthcare infrastructure are expected to propel the growth of the amniotic fluid stem cell therapy market.

However, on the basis of geography, global Amniotic Fluid Stem Cell Therapy Market is segmented into six key regionsviz. North America, Latin America, Europe, Asia Pacific Excluding China, China and Middle East & Africa. North America captured the largest shares in global Amniotic Fluid Stem Cell Therapy Market and is projected to continue over the forecast period owing to technological advancement in the healthcare and growing awareness among the population towards the new research and development in the stem cell therapy. Europe is expected to account for the second largest revenue share in the amniotic fluid stem cell therapy market. The Asia Pacific is anticipated to have rapid growth in near future owing to increasing healthcare set up and improving healthcare expenditure. Latin America and the Middle East and Africa account for slow growth in the market of amniotic fluid stem cell therapy due to lack of medical facilities and technical knowledge.

Some of the key players operating in global amniotic fluid stem cell therapy market are Stem Shot, Provia Laboratories LLC, Thermo Fisher Scientific Inc. Mesoblast Ltd., Roslin Cells, Regeneus Ltd. etc. among others.

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

See more here:
The Amniotic Fluid Stem Cell Therapy Market to Cascade the Success Trove - The Haitian-Caribbean News Network

Skin Stem Cells Comments Off on The Amniotic Fluid Stem Cell Therapy Market to Cascade the Success Trove – The Haitian-Caribbean News Network | December 2nd, 2020

The globalAnti-Ageing Drugs marketreport offers a deep analysis of the global Anti-Ageing Drugs market. It demonstrates a brief summary of industry data and key nomenclature of the market. The report has highlights well-known performers from the global market together with their contribution to the market to determine their progress within the estimated time.

The most preeminent Anti-Ageing Drugs market players are Nu Skin, BIOTIME, INC., DermaFix, Unity Biotechnology, LORAL, Frequency Therapeutics, Elysium Health Inc., Nuritas, Calico, Revision Optics, Elysium, La Roche-Posay. The global Anti-Ageing Drugs research report covers recent improvements while predicting the growth of the main players along with their market shares.

Free Access to the sample pages of the report at

The report estimates the global Anti-Ageing Drugs market volume in the earlier years. It assesses the global Anti-Ageing Drugs market on the basis of returns [USD Million] and quantity [k MT]. The study emphasizes the main constraints and devices determining the market growth. It also determines the valuation of the global Anti-Ageing Drugs market for the predicted time. The report covers the growing movements along with the key opportunities for the development of the global Anti-Ageing Drugs market.

The global Anti-Ageing Drugs market research report covers the key product category and sections Serums and supplements, Antioxidants and enzymes, Stem cells and drugs as well as the sub-sections Skin and hair, Skeletal and muscles, Age-related disorders, Others of the global Anti-Ageing Drugs market. The complete classification of the Anti-Ageing Drugs market is available in the global report related to the analytics of the restraining and supporting factors of the market.

Ask Any Kind of Query Before Purchasing the Report Here::https://www.marketresearchstore.com/report/global-anti-ageing-drugs-industry-market-2019-industry-684907#InquiryForBuying

How will this Market Intelligence Report Benefit You?

1. The report offers statistical data in terms of value (US$) and Volume (units) for the global Anti-Ageing Drugs market today and to 2026.

2. Exclusive insight into the key trends affecting the Anti-Ageing Drugs industry, although key threats, opportunities and disruptive technologies that could shape the global Anti-Ageing Drugs market supply and demand.

3. The report tracks the leading market players that will shape and impact the global Anti-Ageing Drugs market most.

4. The data analysis present in the Anti-Ageing Drugs report is based on the combination of both primary and secondary resources.

5. The report helps you to understand the real effects of key market drivers or restrainers on Anti-Ageing Drugs business.

The global Anti-Ageing Drugs market classification is based on the variety of products and end-user request sections. The market study includes the development of each section of the global Anti-Ageing Drugs market. The data summarized in the report is a collection of variant manufacturer bodies to approximate the growth of sections in future time.

The global Anti-Ageing Drugs market report evaluates the market development across foremost zonal sections. It is divided on the basis of topography as Europe, North America, Latin America, Asia Pacific, and Middle East & Africa. The report embraces the spirited circumstances obtainable in the global Anti-Ageing Drugs market.

Read Detailed Index of full Research Study at::https://www.marketresearchstore.com/report/global-anti-ageing-drugs-industry-market-2019-industry-684907

Read more from the original source:
Global Anti-Ageing Drugs Industry Market Growth Graph To Demonstrate Inclination Towards Positive Axis By 2026 - The Courier

Skin Stem Cells Comments Off on Global Anti-Ageing Drugs Industry Market Growth Graph To Demonstrate Inclination Towards Positive Axis By 2026 – The Courier | December 2nd, 2020

Graft Versus Host Disease (GVHD) Epidemiology

According to the National Cancer Institute (NCI), Graft versus host disease (GVHD) is a disease caused when cells from a donated stem cell graft attack the normal tissues of the transplant patient. Symptoms include jaundice, skin rash or blisters, a dry mouth, or dry eyes. GVHD occurs when particular types of white blood cells (T cells) in the donated bone marrow or stem cells attack the host body cells because the donated cells (the graft) see the host cells as foreign and attack them.

GVHDhas two types Acute GVHDand Chronic GvHD. Acute GvHD is also known as fulminant GVHD and occurs usually in the initial 2-3 months after transplantation. Chronic GVHD occurs around 3-4 months after the transplantation has happened, and has more diverse complications. This type affects the liver, stomach, vagina, joints, lungs, gut, mouth and glands secreting mucus or saliva.

Get FREE sample copy at:https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-epidemiology-forecast

DelveInsights Graft Versus Host Disease (GVHD) Epidemiology Forecast to 2030 report delivers an in-depth understanding of the disease, historical and forecasted Graft Versus Host Disease (GVHD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.The DelveInsight Graft Versus Host Disease (GVHD) epidemiology report gives a thorough understanding of the Graft Versus Host Disease (GVHD) disease symptoms and causes, along with the risk factors, diagnosis, pathophysiology associated with the disease, and. It also provides treatment algorithms and treatment guidelines for Graft Versus Host Disease (GVHD) in the US, Europe, and Japan. The report covers the detailed information of the Graft Versus Host Disease (GVHD) epidemiology scenario in seven major countries (US, EU5, and Japan).

Key Highlights Of The Report

As per a study by Elgaz S. et al., (2019), GVHDoccurs in 3050% of recipients and 14% of all patients suffer severe GVHDgrades 34. Chronic GVHDaffects 3070% of patients receiving allo-SCT.

As per a study by Jacobsohn and Vogelsang (n.d.) titled Acute graft versus host disease, in the United States, approximately 5,500 patients/year can develop acute GVHD and in 2003, the incidence of grade II-IV acute GVHD was roughly 3550%.

As per Orphanet, about 35%-50% of hematopoietic stem cell transplant (HSCT) recipients will develop acute Graft versus host disease (GVHD). And about 50% of patients with acute GVHD will eventually have manifestations of chronic GVHD.

Graft Versus Host Disease (GVHD) Epidemiology

Scope of the Report

Key Benefit of Graft Versus Host Disease (GVHD) Epidemiology Report

The Graft Versus Host Disease (GVHD) Epidemiology report will allow the user to

Get FREE sample copy at:https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-epidemiology-forecast

Table of Contents

*The table of contents is not exhaustive; will be provided in the final report

Related ReportsGraft versus host disease (GVHD)- Market Insight, Epidemiology and Market Forecast -2030DelveInsight s Graft versus host disease (GVHD) Market Insights, Epidemiology and Market Forecast 2030 report provides a detailed overview of the disease and in depth understanding of historical and forecasted epidemiology.

Graft versus host disease (GVHD) Pipeline Insights, 2020Graft versus host disease (GVHD) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Graft versus host disease (GVHD) market.

About DelveInsightDelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact usShruti Thakur[emailprotected]+91-9650213330https://www.delveinsight.com/LinkedIn | Facebook | TwitterGraft Versus Host Disease (GVHD) Epidemiology Report:https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-epidemiology-forecast

See original here:
Graft Versus Host Disease (GVHD) Patient Population, Treatment Algorithm, Medical Practices And Epidemiology Forecast To 2030 - The Market Feed

Skin Stem Cells Comments Off on Graft Versus Host Disease (GVHD) Patient Population, Treatment Algorithm, Medical Practices And Epidemiology Forecast To 2030 – The Market Feed | December 2nd, 2020

Medical skin care products are used for beautifying or to address some other skin care problems. The cosmetic industry is booming and skin care forms a very huge part of this industry. The aesthetic appearance is so important that people spend a lot on skin care products and treatment. People being more technologically aware of the various new skin care products trending in the market. In addition to the aesthetic application, the medical skin care products are also used to address issues such as acne, pimples or scars.

Medical Skin Care Products Market: Drivers and Restraints

The medical skin care products is primarily driven by the need of natural based active ingredients products which are now trending in the market. Consumers demand medical skin care products which favor health and environment. Moreover, the consumers are updated with the trends so that various companies end up providing such products to satisfy the customers. For instance, a single product face mask has thousands of different variants. This offers consumers different options to select the product depending on the skin type. Moreover, the market players catering to the medical skin care products are offering products with advanced technologies. For instance, Santinov launched the CICABEL mask using stem cell material based on advanced technologies. The stem cells used in the skin care product helps to to protect and activate the cells and promote the proliferation of skin epidermal cells and the anagenesis of skin fibrosis.

To remain ahead of your competitors, request for a sample[emailprotected]

https://www.persistencemarketresearch.com/samples/18469

Medical Skin Care Products Market: Segmentation

On the basis of product type the medical skin care products market can be segmented as:

On the basis of application, the medical skin care products market can be segment as:

On the basis of distribution channel, the medical skin care products market can be segment as:

Medical Skin Care Products Market: Overview

Medical skin care products are used to address basic skin problems ranging from acne to scars. There are various advancements in the ingredients used to offer skin care products to the consumers. For instance, the use of hyaluronic acid and retinoids is the latest development in the industry. The anti-aging creams are at the forefront as the help treating issues such as wrinkles, scars, acne, and sun damage. Another, product in demand is the probiotic skincare which include lactobacillus and bifidobacterium.

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/18469

Medical Skin Care Products Market: Region-wise Outlook

In terms of geography, medical skin care products market has been divided into five regions including North- America, Asia- Pacific, Middle-East & Africa, Latin America and Europe. North America dominated the global medical skin care products market as international players are acquiring domestic companies to make their hold strong in the U.S. LOral is accelerating its U.S. market by signing a definitive agreement with Valeant Pharmaceuticals International Inc. to acquire CeraVe, AcneFree and Ambi skin-care brands for US$ 1.3 billion. The acquisition is expected LOreal to get hold of the brands in the price-accessible segment. Asia Pacific is expected to be the fastest growing region owing to the increasing disposable income and rising awareness towards the skin care products.

Medical Skin Care Products Market: Key Market Participants

Some of the medical skin care products market participants are Avon Products Inc., Beiersdorf AG, Colgate-Palmolive Company, Kao Corporation, LOral S.A., Procter & Gamble, Shiseido Company, The Estee Lauder Companies Inc., Unilever PLC, Revlon, Clinique Laboratories, llc., Murad, LLC., SkinCeuticals, RMS Beauty, J.R. Watkins and 100% PURE.

You Can Request for TOC Here @https://www.persistencemarketresearch.com/toc/18469

Explore Extensive Coverage of PMR`s

Life Sciences & Transformational HealthLandscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor, New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

Go here to read the rest:
The end-use Industries to Help the Medical Skin Care Products Market stand in a good stead between 2017 and 2025 - Cheshire Media

Skin Stem Cells Comments Off on The end-use Industries to Help the Medical Skin Care Products Market stand in a good stead between 2017 and 2025 – Cheshire Media | November 30th, 2020

By Mark Philips.

New York - November 30th, 2020 - To put it simply, it concerns nanotechnological research, its adaptation and then application in cosmetology. Nanoasia, under the management of Kira Sorokina, was one of the first international companies to work in this field when it started more than five years ago. Nanoasia is a brand of exclusive cosmetics for use in salons and at home, which was the first to test and bring airbrush non-injection anti-ageing products to the market.

The secret lies in tiny nano particles, each around 4 nanometers in length (and so therefore smaller than the diameter of even the driest skin pores). This means that the active components can penetrate deeper into the skin without needing to use an injection, mentioned Kira Sorokina. The product contains peptides, biosynthesized from plants, amino acids (proteins) and plant extracts of the highest quality. It is important to note that Nanoasias ingredients are all able to serve their complex individual function due to the balanced recipe, which ensures that every ingredient compliments and enhances the others. This is why just a handful of components can come together to provide an integrated product that solves all of the most common issues, she added. Despite Nanoasia being produced in South Korea, using their technologies, all of the formulas are adapted to the needs of European skin types. The device and cosmetic products, developed and produced by Nanoasia, are designed to work with the skin, skin cells and facial muscles.

Now lets take a closer look at Nanoasias innovative components and how they work!

Nanoasias serums (which are currently produced in three distinct varieties) represent the new generation of non-injection bio-revitalizers. These unique plant-based nanocomplexes contain a high concentration of nano-peptides, amino acids and plant extracts. They target all of a skins age-related changes, penetrating directly into the dermis and working instantly from the first application! They can correct the faces oval shape, tightening the cheeks and restoring their elasticity. They iron out any smile lines and baggy skin under the eyes, whilst also helping lose any facial fat (by improving blood circulation and lymphatic drainage). They nourish and rejuvenate the skin at a cellular level. They help to lighten up any pigment stains and bleaching. They help to prevent muscular spasms, preserving your natural facial expressions, reducing puffiness and dark circles under the eyes. They restore the cellular structure of collagen fibers, preventing the sebaceous glands from becoming overactive. They enhance cell regeneration, removing any pigment stains and rebuilding the structure of the dermis.

Nanoasia has developed a unique device to allow these special serums to penetrate deep into the skin. Simply put, it is a portable compressor, suitable for use at a salon or, indeed, at home. Thanks to the products low-molecular composition and the tiny dimensions of the particles, non-injection mesotherapy using Nanoasias serums easily gets into the deeper layers of the skin, helped by the compressed air brush. The procedure of applying the product to the skin with a strong jet of air is as painless as can be.

Besides the serums, Nanoasia also produces many incredible products which work on both the dermis and the facial muscles. Our mousse, enzyme exfoliating roll and the serum effectively clean and maintain the skin thanks to their Air Bubbles technology. This is the ideal base care for everyone - deep and delicate cleansing, intense moisturization, nourishment and stimulation to help the skin become rejuvenated and regenerated. This all comes from the high concentration of peptides, amino acids and plant extracts.

The product containing nanoneedles (cream + serum) has a comprehensive effect: it lifts and rejuvenates the skin, eliminating wrinkles and pigmentation, improving skin tone and elasticity. It provides nutrition and protection to the skin, thanks to the inclusion of plant extracts, amino acids and the self-soluble nanoneedles (compounds derived from seaweed which ensure that the nutritional components can penetrate as far as possible into the skin).

Nanoasias creams have a unique formula. The My Che duet (cream for the skin around your eyes and face), our EVA body cream and VS - our air-cushioning cream - are all the first of their kind in the world. They contain a high concentration of amino acids (the building blocks of our very organisms), peptides and plant stem cell extracts from a 100 year old ginseng plant and a 1000 year old yew tree. The formulas of these products guarantee rejuvenation, recovery and care from within, at a cellular level, giving you a powerful lifting effect, nourishment, protection and ironing out any wrinkles, pigments and much more. Air Cushion is also SPF 50+ and contains UV protection thanks to its intelligent fluid formula and nano-particle technologies. This ensures the ideal coverage for every day, without clogging or overwhelming the pores. It is a light foundation with an almost weightless texture and is compatible with any skin color when heated.

Their products pay special attention to your facial muscles. Their mask contains 45 active components including peptides, extracts from gem stones and plants. The mask stimulates isometric pressures within the skin. The muscles pulsate against this pressure with the uniform pressure acting like yoga for the face. The muscles then become toned and stronger. Facial and dermal muscles are smoothed out, skin elasticity is restored, the youthful oval shape of one's face returns and double chins are removed. Our Nanolifting system for Youthful Skin is a revolutionary lifting mask forone's facial muscles and dermis, containing powerful antioxidant and antiseptic components. The mask contains the highly-prized components of Astragalus root extract, Trehalose, 9 different peptides and 12 plant extracts which combine to achieve the following: they slow down the ageing process of cells; kickstart the extracellular matrix; regulate the tension of the vascular wall (Rosacea) and stimulate the restoration of the structural elements of the dermis - collagen, elastin, fibronectin and glycosaminoglycans.

Besides its exterior care potential, Nanoasia also looks after the skin from within. To achieve this they have developed unique products, including a bio-active additive (Nanodessert Nutritional) and a youthful elixir (Nanocell Youth Elixir).

Nanoasia holds three patents for cutting-edge research in cosmetology, as well as having a few further patents pending approval. The company has not only won praise in Russia, CIS countries and Europe, but also made it to Canada and Panama, and it is expected to open a branch in the United States soon expressed Kira; today, Nanoasia has 60 representatives in 28 cities and 8 countries. Our brands mission is to give every woman the opportunity to hold onto her natural beauty for as long as possible.

Media ContactCompany Name: Prysma MediaContact Person: Mark PhilippsEmail: Send EmailCountry: United StatesWebsite: https://nanoasia.ru/

Read the original here:
What exactly is the revolutionary Smart Beauty Technology, and how Kira Sorokina, the Founder of NanoAsia leads it - Press Release - Digital Journal

Skin Stem Cells Comments Off on What exactly is the revolutionary Smart Beauty Technology, and how Kira Sorokina, the Founder of NanoAsia leads it – Press Release – Digital Journal | November 30th, 2020

Chronic inflammation in the body is linked to cancer, heart disease, diabetes and more, and recently, scientists have discovered that inflammation is also one of the main culprits of skin aging.But what causes it and how do we stop it from getting worse? Weve got the answers below.

Why Inflammation OccursAccording to San Diego, CA dermatologist Zenovia Gabriel, MD, in the body, inflammation stems from an increase in oxygen free radicals that subsequently lead to a cascade of downstream cellular effects. The toxic oxygen radicals trigger inflammatory signals that lead to a host of negative cellular responses, she explains. Skin inflammation is a result of the immune systems response to stimuli or triggers, serving as a defense mechanism to protect your body against injury, infection or cancer.

There are two types of skin inflammation: acute and chronic. Acute inflammation is your bodys immediate response to a physiological insult such as an infection, trauma, stressanything that disrupts your immune system, says Dr. Zenovia. The body expresses inflammation by tissue swelling, warmth, pain or redness, as well as systemic symptoms like fever, aches and fatigue.

Acute inflammatory symptoms generally minimize after several days and eventually normalize, but chronic inflammation implies a longstanding issue that Dr. Zenovia says is often caused by underlying conditions such as autoimmune disorders or chronic infections. Chronic inflammation can be worsened by environmental stressors or unhealthy lifestyle habits, she adds. As we age, our bodies become less efficient at managing the inflammatory response. In addition, chronic low-grade inflammation is common as we age because our bodies and cells are less efficient at regulating this process.

Our diets play a role, too: High blood sugar and poor diet can result in a process called glycation. This leads to protein malfunction in the cells, causing a disruption to normal function, says Dr. Zenovia. In effect, if your body is inflamed and cant handle the level of inflammation, then there are consequences at the cellular and then tissue levelsthis is what we see and feel. We see the cellular disruption manifested on our skin. And these symptoms, such as sagging, wrinkles and brown spots, are all manifestation of cellular disruption and inflammation.

How It Impacts Our SkinThe process is coined inflamm-aging because inflammation ages us, says Dr. Zenovia. Acute inflammation can manifest on the skin as a rashsmooth or scalyredness or warmth in the affected area. Mild low-grade chronic inflammation, such as rosacea or undetectable sun damage often causes skin dryness, dullness, uneven tone, texture, loss of elasticity, or fine lines and wrinkles.Therefore, antioxidants and other actives that specifically target inflammation in the skin are a new frontier for anti-aging. Its not just moisturizers, retinols and hydroxy acidswe need anti-inflammatory support for our skin too.

That undetectable sun damage plays a significant role in the inflammation process. Inflammation is thought to be one of the main causes of skin aging, and the constant exposure to UV radiation from the sun can cause inflammation and DNA damage in the skin, leading to fine lines, wrinkles and spots, says Fort Lauderdale, FL dermatologist Dr. Matthew J. Elias.The single most important product we recommend for skin aging is sunscreen, and while any sunscreen will help protect skin from the untoward effects of chronic UV exposure, the only sunscreen that can actually repair the DNA damage done by the sun is ISDIN Eryfotona Actinica, which actually contains DNA repairsomes that can repair the damage caused by the sun and lessen inflammation.

Dr. Zenovia says an inflammatory cascade can also cause the body to produce more hyaluronidase, the enzyme responsible for breaking down hyaluronic acid (HA), which is critical to skin thickness and health. Fibroblastscollagen-producing cellsare also affected by inflammation, and can become damaged and produce less collagen, she explains. This causes skin to lose its firmness and elasticity.

How to Minimize the EffectsThe first brand to put inflamm-aging skin care on the map, Heraux created a patented molecule called HX-1 that gently exfoliates the skin while helping to prevent inflammation, which is the key ingredient in its Molecular Anti-Inflammaging Serum. HX-1 works directly on skin stem cells to support their peak performance and shield them from stressors that can promote irritation, says Ben Van Handel, PhD, cofounder of Heraux and stem cell biologist at the University of Southern California. Clinical studies of HX-1 have shown significant improvements occurringin the first four weeks without any skin irritation. Daily use of the serum will enable youthful function of skin stem cells longer, increasing the health span of the skin.

Dr. Amir Nobakht, cofounder of Heraux, says its an alternative to retinol without the potential side effects. Retinols historically have had good results but also cause irritation, redness and sun sensitivity, making them unusable for many people. HX-1 on the other hand can accomplish the same goals of a retinol without the harsh side effects. Even those with sensitive skin or who are prone to sunburns can get results without worrying.

One of Dr. Zenovias bestsellers in her Essentials line, Inflam-Aging Night Repair Treatment specifically targets inflammation and is clinically formulated to combat key signs of aging. Everyone could benefit from this product: acne, aging, young and old, she says. This powerhouse night repair treatment features a highly potent triple antioxidant blend of green tea polyphenols, medical-grade resveratrol and caffeine to help reduce inflammation while reducing the appearance of fine lines and wrinkles, and enhancing the look of firm, plump, even-toned skin. Sleep is also really important. Its one of the most restorative things we can do for our bodies and our skin. It decreases stress, lowers inflammation and regenerates our cells.

At NewBeauty, we get the most trusted information from the beauty authority delivered right to your inbox

Find a NewBeauty "Top Beauty Doctor" Near you

See the original post:
Everything to Know About Inflamm-aging - NewBeauty Magazine

Skin Stem Cells Comments Off on Everything to Know About Inflamm-aging – NewBeauty Magazine | November 25th, 2020

Detroit Lions senior VP of business development Kelly Kozole works with her daughter, Morgan, who has a rare neurological disorder called beta-propeller protein-associated neurodegeneration, or BPAN.Michael Rothstein

TROY, Mich. -- Wearing a white T-shirt with a massive star in sparkling shades of pink, yellow and seafoam green on the front, Morgan Kozole sits in front of a fold-up chalkboard in the living room of her family's Detroit-area home and starts to draw.

Using pink and yellow chalk, she sketches Mickey and Minnie Mouse. The Disney characters are dominant fixtures in the 5-year-old's life and therefore become a soundtrack for the Kozole family: Morgan constantly saying "Mickey," with her long, blond ponytail bouncing to whatever song happens to be playing on the Mickey Mouse Club.

"These are the two Mickeys," Morgan says, pointing to the chalkboard. Her mother, Detroit Lions senior vice president of business development Kelly Kozole, explains that this is her way of communicating that she would like a visitor to draw Mickey too. If it's close, Morgan accepts it. Another Mickey to fawn over.

For Morgan's birthday earlier this year, the family went to Disney World. On this trip, the Kozoles saw what they had longed for: the potential of progress.

"She knew where we were. She knew Mickey Mouse," Kelly said. "Before, she wouldn't go to the characters, and now she's jumping up and down, hugging. She really, along those lines, is also really into birthdays.

2 Related

"The 'Happy Birthday' song. Before that, she was just kind of looking. Sometimes it was too much for her with everyone singing -- sometimes loud noises are too much. This year, we had to sing 'Happy Birthday' to her three times."

Birthdays, for children, are happy occasions -- reasons for grand celebrations of progress toward adulthood. For the rest of Morgan's family it is more complicated.

Morgan has a rare neurological disease called beta-propeller protein-associated neurodegeneration, known as BPAN. It's a disorder, more prevalent in girls than boys, that causes delayed development and seizures, communication issues and, sometimes, motor dysfunction. It's unclear exactly how many people are living with BPAN worldwide due to its rarity, although Dr. Sami Barmada, a scientist at the University of Michigan studying BPAN, estimates roughly 500 to 600 people.

It's rare enough that Dr. Henry Paulson, the director of the Michigan Alzheimer's Disease Center, said there are experts in neurodegeneration who are unfamiliar with BPAN. While Kelly is trying to advocate for her daughter and others with BPAN through fundraising for research, science moves only so fast.

The Kozoles understand that. So birthdays for the family aren't always happy. They are a reminder of what could come.

"That ticking time clock," Kelly said. "Every birthday isn't exciting for me for her. Because it's one year closer to when this bomb is going to go off."

BPAN's rarity makes the reality heartbreakingly simple: There are very few effective treatments, little research and no cure. As Morgan learns how to organize her Peppa Pig characters and learns new words on her iPad -- her future looms.

At some unpredictable point in Morgan's teen and adult years -- the average is around age 25, according to Barmada -- development will just stop. Progress will decline and, in some cases, disappear. Those afflicted with BPAN begin suffering from progressive dystonia parkinsonism -- making it difficult to walk, talk or stand.

"Any day," Kelly said, "it could be like, 'Oh, your daughter's gone.'"

WHEN MORGAN WAS born on Jan. 12, 2015, she was, largely, a healthy baby. She was a little jaundiced but nothing worrisome.

When she would go to the doctor's office for shots, Morgan didn't cry. It was a little abnormal, but when you're a parent of a young child, no crying is viewed as a minor miracle. Kelly and her husband, Kevin, took this as a sign of a tough kid. Nurses even said how great it was.

Looking back, it was a warning sign that something was wrong. BPAN causes a high pain tolerance. Before long, more concerns popped up. Morgan wasn't crawling at nine months, wasn't walking at a year. Expected milestones passed without Morgan reaching them. Kevin and Kelly put her in therapy in late 2016 to work up to these childhood progressive traits and began researching potential causes. They wouldn't find an answer for more than two years.

"She was diagnosed with cerebral palsy at first. One doctor diagnosed her with that, and then another, our neurologist, said she doesn't have that," Kelly said. "Then there was speculation but not a full diagnosis she had autism, so we did all the tests for that.

"So through this kind of journey of trying to find out what was wrong, it was exciting that she didn't have something that you were going to this test for, but you still had so many more questions as you were eliminating all these potential diseases that she could have."

Befuddled, they began genetic testing and in November 2018 received a letter about a mutation on Morgan's WDR45 gene. Kelly Googled it, stumbled upon BPAN and freaked out, calling their neurologist. The neurologist told Kelly not to worry -- BPAN was very rare, and Morgan didn't have it.

Doctors diagnosed her with epilepsy because of seizures. Morgan took Keppra, which helped accelerate her vocabulary to about 50 words, typical for a 1-year-old, when she was 3. Then doctors said no, it wasn't epilepsy either.

Here's how the postseason bracket looks at the moment and what scenarios lie ahead. Playoff picture (ESPN+) Playoff Machine: See scenarios Standings | Football Power Index

Another meeting with another neurologist led to a different diagnosis. Three days after she and Kevin returned to Michigan from Super Bowl LIII in February 2019, they received a call. Doctors figured out what was wrong.

It was BPAN.

"In my mind, it's worse than cancer," Kelly said. "How is this even possible? That this can even be so painful for kids later on in life. You try so hard to gain all these abilities, and then early adolescence or early adulthood, it's just [gone] one day, and I've seen a lot of these stories.

"There's a BPAN Facebook website, and that's where the doctors sent us. There's no cure. There's no therapy. 'Go to this website.' That's what I was told."

FOR MONTHS KELLY cried, angry and heartbroken. The Kozoles initially told their families and no one else.

In May 2019, Kelly went to her first Neurodegeneration with Brain Iron Accumulation (NBIA) conference. She met other parents, heard their stories and began the new normal.

She used her skills -- organization, fundraising and business -- to brainstorm ways to help. Hardly anyone had researched BPAN. Without it, there would be no chance for a cure -- not in Morgan's lifetime, which could reach her 40s, and not in the lifetime of those who might come after.

She shared what was happening with her boss, Detroit Lions president Rod Wood, and his wife, Susan, using a website link to explain BPAN. Wood knew something was wrong because of texts and emails saying they had to take Morgan to this specialist or that appointment.

"As that was confirmed and became her reality, she is now able to talk about it, in a way," Wood said. "Because she's full bore on trying to help generate awareness and financial resources to find a cure for it.

"She went from the unknown to the very tragic known to, 'OK, what are we going to do about it?'"

Kelly consulted her aunts, both of whom worked in medicine. Linda Narhi worked in biotechnology for Amgen for more than 30 years; Dr. Diane Narhi was the first female chief of staff at Simi Valley (California) Hospital. From talking with another group of fundraising BPAN parents -- BPAN Warriors -- Kelly found a guide.

If her aunts had not been resources, she might have joined BPAN Warriors. But Kelly admittedly needs to be in control, and this was her daughter. She needed to manage this herself. She created a nonprofit called Don't Forget Morgan.

Kelly's aunts provided guidance, and Wood offered contacts he had in the finance industry and Silicon Valley. Wood and Lions general counsel Jay Colvin sit on the board. Other Lions coworkers -- with Wood's blessing -- built the website, designed the logo and created social media plans and the first pitch video for Don't Forget Morgan's rollout in 2020.

Everything you need this week: Full schedule | Standings Depth charts for every team Transactions | Injuries Football Power Index rankings More NFL coverage

Progress started with a $15,000 grant to help with a mouse model study at Sanford Research in South Dakota, with another, larger, potential grant to come. In recent months, Kelly has focused largely on fundraising, and another parent of a child with BPAN, Christina Mascarenhas Ftikas, has focused on the medical side of the nonprofit.

"This is why I'm here," Kelly said. "I'm supposed to be a vehicle to get all of this awareness and hopefully a cure for BPAN so the child one, two, three, five years from now, there is hope.

"There is no, 'Go to Facebook.' There is something where you can actually give a parent, 'Here's the symptoms to look for.'"

ABOUT AN HOUR away in Ann Arbor, Michigan, Kaci Kegler and her husband, Brian, had been in the same Facebook community. Kelly, new to the group and looking for a nearby connection, wrote Kaci a message.

"Hey, my daughter was just diagnosed, could we connect?"

Kaci understood. She did the same thing, reaching out without success in 2016 after her daughter, Elle, was diagnosed. Kaci wanted to be a resource.

They talked for an hour. There wasn't much Kaci could say to soothe her. Kelly pinged a year later with another message: I'm starting a nonprofit. Kaci offered to help.Despite suffering from BPAN, Morgan is like any other 5-year-old who enjoys playing with her brother, Connor.Michael Rothstein

Days later, on Feb. 28, Kaci and her husband, Brian, an assistant athletic director for development at the University of Michigan, had their yearly fundraiser for BPAN research on Rare Disease Day at Pizza House in Ann Arbor. They met a doctor who had a connection to researchers at Michigan.

"I literally came home and texted [Kelly] and was like, 'Oh my gosh, we may have inroads,'" Kaci said. "We just started texting. I have never met Kelly face-to-face. We still haven't. But we've texted a lot and we've emailed quite a bit.

"It just kind of started."

By summer, they went from nothing to putting pieces in place for a full-fledged research project with a two-year, $140,000 grant for Barmada and Dr. Jason Chua to help start to solve BPAN.

Chua was working on the regulation of autophagy, which is the cleaning out of damaged cells, and studying BPAN became a natural extension of the work he had already been putting in. BPAN alters that in neurons. Barmada said Chua's research provided a "rare win-win situation" to potentially help with BPAN and other diseases too.

"There are a set of questions in BPAN that nobody has the answer to," Barmada said. "And Jason and myself, we just seem to be in the right position, the right place to be able to help out."

The goal is to understand what is happening within BPAN itself and how people end up with it, while also trying to find therapies for existing patients. Within a year, they are hoping to grow stem cells from people with BPAN in their lab, allowing for the creation of their own stem cells missing the WDR45 gene. Then they will try to either replace the gene or "stimulate autophagy through genetic or pharmacologic means," Barmada said. The hope is this can prevent neurodegeneration.

So far, they've hired a research assistant to work with Chua, developed tools to manipulate the gene using the genome-editing tool CRISPR and applied for approval from Michigan and the institutional review board to get skin biopsies to obtain stem cells from BPAN patients.

It's a process, but it's also a start.

When RGIII was like Mike Vick in 2012 Cards' Kingsbury knew he wasn't Brady Colts rookies surging to head of class Bolts' Ekeler discusses hamstring tear Should Jets shut down Sam Darnold?

After partnering with Michigan and Sanford, Don't Forget Morgan also began working with Dr. Kathrin Meyer, a researcher at the Center for Gene Therapy at Nationwide Children's Hospital at Ohio State.

"Solving this disease is going to require more than Jason and Sami," Paulson said. "It's going to be a first shot across the bow, but it's going to require more than that. I'll say this, being in the field for a long time. Scientists who are coming up the pike say they want to look at Alzheimer's, want to look at epilepsy. They don't say, 'I want to look at a rare disease.'

"The only way to solve a rare disease is to get someone hooked. Sometimes when you hook a really good one, as I think we have with Jason here, you hook them for life and they make a difference."

MORGAN IS BOUNCING around the Kozoles' suburban Detroit home on this late August day. They just returned from northern Michigan, and having two kids, especially one with special needs, makes tidiness unrealistic.

COVID-19 changed things. Morgan hadn't been to many of her therapies for months. Online school barely kept her attention. There was concern she would have regression in her learning. Instead, her speech advanced by being around Kelly, Kevin and her older brother, Connor, all day. She has sung more songs recently to help increase her vocabulary. Sometimes, she'll listen 20 times in a row.

"Even more than that," Connor said. They aren't sure how much she's truly learning versus memorization. But it is something.Morgan Kozole has inspired her mother, Detroit Lions VP Kelly Kozole, to marshal researchers and other advocates to develop a cure for BPAN, and perhaps help future generations of children who live with the disorder.Michael Rothstein

The family gathers inside Morgan's bedroom -- complete with a special Haven Bed with a zipper to keep her safe from wandering around at night, when she could accidentally turn on the stove and hurt herself or others -- sleep disorders are another BPAN issue. She sits on the floor and starts playing with her small, yellow dollhouse and a fake ice-cream maker. Kelly asks for an ice cream. Morgan makes one for herself instead and pretends to eat it.

Later, outside, Morgan kicks a soccer ball and plays a modified game of catch with a squishy football. Football, no surprise, is big. She says "hike" a lot. "She knows that term," Kevin says, laughing.

In these moments, Morgan seems like any other young child. She attends St. Hugo of the Hills Parish School in Bloomfield Hills, Michigan, but has a one-on-one para nanny to help. She interacts with people, often overly affectionate.

Sitting at the kitchen table after playtime outside, she plays with Starfall, a children's learning app, on her iPad. They hope it accelerates her word recognition. Morgan is entranced watching "Farmer in the Dell" and using her hands to eat orange slices and Cheerios. She needs a mirror in front of her to provide her a target for her mouth. She listens to books, another way to try absorbing information.

Morgan can now count to 20 and say three sentences in a row. Kelly and Kevin have tried to give Morgan a normal life in an abnormal situation, but they worry about the future -- what she won't have and won't be able to experience.

But Morgan has changed some of that outlook too.

"Focus on how she is so loving and has so much pure joy. A lot of parents of special needs [kids] say you can learn so much from these kids, and you really can," Kelly said. "She is, every morning, just so happy, and 'Mama!' Hugs and kisses to strangers. She has none of those behaviors you learn as an adult where you're not kind to people or you don't want to talk to someone.

"She is just open arms, will give you a hug and is so loving, and it's like, 'Wow, this is really what life is about.'"

Go here to read the rest:
'This is why I'm here': A Detroit Lions VP tries to save her daughter from rare disease - ESPN

Skin Stem Cells Comments Off on ‘This is why I’m here’: A Detroit Lions VP tries to save her daughter from rare disease – ESPN | November 25th, 2020

Want to go back in time and look younger? Thats possible now. Yes, you read that right. In a path-breaking discovering, Israeli scientists have made reverse ageing possible. They have found a way to make you look up to 25 years younger. Also Read - Weight Lifting, Sleeping Face-Down And More: Here're 5 Lifestyle Habits That May be Ageing Your Skin

Researchers at Tel Aviv University and the Shamir Medical Centre have collaboratively conducted a study for which they enrolled 35 adults over 64. The subjects were given hyperbaric oxygen treatments (HBOT) 5 times a week for 90 minutes. This continued for three months. Later, the study results published in the journal Ageing showed that the use of this oxygen treatment shortened the ends of the chromosome (telomers) and reversed the accumulation of old body cells. Also Read - 3 Anti-Ageing Essential Oils That Can Offer You Youthful Skin

Notably, ageing depends upon sequences of DNA called telomeres. They are located at the ends of chromosomes and their function is to protect the genetic material contained within. These telomeres shorten and degrade every time a cell divides. This process keeps happening until they become so worn down that they can no longer function. This further results in an unstable or dead chromosome. Also Read - 5 Anti-Ageing Food Items You Must Include in Your Diet to Look Young

One of the study researchers named Professor Shai Efrati said, Today telomere shortening is considered the Holy Grail of the biology of ageing. Researchers around the world are trying to develop pharmacological and environmental interventions that enable telomere elongation. Our HBOT protocol was able to achieve this, proving that the ageing process can, in fact, be reversed at the basic cellular-molecular level.

Hyperbaric Oxygen Treatment (HBOT) is a type of therapy during which a patient is kept in a pressurized chamber where the level of oxygen is increased 3 to 4 times more than what you can breathe at normal air pressure. This aims at treating patients suffering from decompression sickness, brain abscess, severe anemia, who have developed air bubbles in their blood vessels, non-healing wounds, radiation injury, vision loss etc.

When your body gets extra oxygen, it releases growth factors and stem cells that are known to promote healing. In a normal scenario, the oxygen you get through the air is adequate for your body to perform different functions. However, when tissue in your body gets damaged or injured, it needs extra oxygen to survive. Through hyperbaric oxygen treatment, doctors temporarily increase the amount of blood your body is carrying and thus helps maintain the oxygen level in tissue to ensure its survival.

More here:
Israeli Scientists Discover Oxygen Beauty Treatment That Can Make You Look 25 Years Younger - All You Need to - India.com

Skin Stem Cells Comments Off on Israeli Scientists Discover Oxygen Beauty Treatment That Can Make You Look 25 Years Younger – All You Need to – India.com | November 25th, 2020

It dawned on Eian Kantor on a Saturday in early April as he brewed a cup of tea from fresh mint leaves: he had lost his sense of smell. The tea suspiciously smelled of nothing at all. Kantor proceeded to rifle through the fridge, sniffing jars of pickles, chili sauce and garlicnothing.

Ever since New York State went into lockdownin late March,Kantor, age 30, and his girlfriend had stayed isolated in their Queens, N.Y., apartment. So he did not suspect he had COVID-19 despite running a slight fever that he chalked up to seasonal allergies. When he was finally able to get tested weeks into his loss of smell, or anosmia, he tested negative. But months later, he says, several tests showed that his antibodies to the novel coronavirus were off the charts high, which affirmed that I had had it.

An estimated 80 percent of people with COVID-19 have smell disturbances, and many also have dysgeusia or ageusia (a disruption or loss of taste, respectively) or changes in chemesthesis (the ability to sense chemical irritants such as hot chilies). Smell loss is so common in people with the disease that some researchers have recommended its use as adiagnostic testbecause it may be a more reliable marker than fever or other symptoms.

One lingering mystery is how the novel coronavirus robs its victims of these senses. Early in the pandemic, physicians and researchers worried that COVID-related anosmia might signal that the virus makes its way into the brain through the nose, where it could do severe and lasting damage. A suspected route would be via the olfactory neurons that sense odors in the air and transmit these signals to the brain. But studies have shown that this isprobably not the case, says Sandeep Robert Datta, a neuroscientist at Harvard Medical School. My gestalt read of the data to date suggests that the primary source of insult is actually in the nose, in the nasal epithelium, the skinlike layer of cells responsible for registering odors. It looks like the virus attacks, predominantly, support cells and stem cells and not neurons directly, Datta says. But that fact does not mean that neurons cannot be affected, he emphasizes.

Olfactory neurons do not have angiotensin-converting enzyme 2 (ACE2) receptors, which allow the virus entry to cells, on their surface. But sustentacular cells, which support olfactory neurons in important ways, are studded with the receptors. These cells maintain the delicate balance of salt ions in the mucus that neurons depend on to send signals to the brain. If that balance is disrupted, it could lead to a shutdown of neuronal signalingand therefore of smell.

The sustentacular cells also provide the metabolic and physical support needed to sustain the fingerlike cilia on the olfactory neurons where receptors that detect odors are concentrated. If you physically disrupt those cilia, you lose the ability to smell, Datta says.

In astudyinBrain, Behavior and Immunity, Nicolas Meunier, a neuroscientist at the Paris-Saclay University in France, infected the noses of golden Syrian hamsters with SARS-CoV-2. Just two days later, about half of the hamsters sustentacular cells were infected. But olfactory neurons were not infected even after two weeks. And strikingly, the olfactory epithelia were completely detached, which, Meunier says, resembled skin peeling after a sunburn. Although olfactory neurons were not infected, their cilia were entirely gone. If you remove the cilia, you remove the olfactory receptors and the ability to detect odorants, he says.

Disruption of the olfactory epithelium could explain the loss of smell. Yet it remains unclear whether the damage is done by the virus itself or invading immune cells, which Meunier observed after infection. Widespread reports of anosmia with COVID are not typical of other diseases caused by viruses. We think its very specific to SARS-CoV-2, Meunier says. In aprevious studywith other respiratory viruses at his lab, he foundsustentacular cells infected only rarely, whereas with SARS-CoV-2, about half of cells contained the pathogen. With other viruses, smell is usually compromised by a stuffed-up nose, but COVID doesnt usually cause nasal congestion. This is very different, Meunier says.

Researchers have found a few clues about the loss of smell, but they are less certain about how the virus causes a loss of taste. Taste receptor cells, which detect chemicals in the saliva and send signals to the brain,do not contain ACE2, so they probably do not get infected by SARS-CoV-2. But other support cells in the tongue carry the receptor, perhaps providing some indication of why taste goes away. (Although taste can seem to disappear with anosmia because odors are such a key component of flavor, many people with COVID truly develop ageusia and cannot detect even sweet or salty taste.)

The loss of chemical sensingthe burn of hot chilies or the refreshing sensation of mintalso remains unexplained and largely unexplored. These sensations are not tastes. Instead their detection is conveyed by pain-sensing nervessome of whichcontain ACE2throughout the body, including the mouth.

More clues to how the virus obliterates smell come from people recovering from anosmia. The majority of patients lose smell like a light switch going off and recover it rapidly, Datta says. Theres a fraction of patients that have much more persistent anosmia and recover on longer time scales. The olfactory epithelium regularly regenerates. Thats the bodys way of protecting against the constant onslaught of toxins in the environment, Meunier says.

Still, more than seven months after he first experienced anosmia, Kantor falls in the second group of patients: he has yet to detect any odors at all. Its hard because you dont realize how much you relate to smell until you lose it, he says. If the house were on fire, I wouldnt know it. Its very concerning. And then there is what anosmia does to the joy of eating. Foods that used to be good now taste meh, Kantor says.

Carol Yan, a rhinologist at the University of California, San Diego, says that anosmia poses a real health risk. It actually increases mortality. If you cant smell and taste food, it can predispose you to harm, like rotten food or a gas leak, she says. It can also cause social withdrawal or nutritional deficits.

The variation on sensory themes extends to another symptom called parosmia, a possible sign of recovery in people with long-lasting anosmia. Freya Sawbridge, a 27-year-old New Zealand woman, is such an individual. She got COVID-19 in March. After several weeks of anosmia and ageusia, when everything tasted of ice cubes and cardboard, she says, Sawbridge began to regain the most basic tastessweet, salty, sourbut no nuance of flavor, which comes from foods aromas. Chocolate tastes like sweet rubber, she says.

Then, after about five months, some odors returned but not as expected. For a while, all foods smelled of artificial strawberry flavor. But now everything smells hideous and distorted, Sawbridge says. Nothing is accurate, and the odors are all unpleasant. The smell of onions, she says, is unbearable, and a strange chemical flavor permeates everything. All my food tastes like it was sprayed with window cleaner, Sawbridge adds.

Parosmia may occur when newly grown stem cells that develop into neurons in the nose attempt to extend their long fibers, called axons, through tiny holes in the base of the skull and connect with a structure in the brain called the olfactory bulb. Sometimes axons connect to the wrong place, causing erratic smell, but the miswiring can potentially correct itself, given enough time.

That news is welcome for people such as Sawbridge. But the question she wants answered is: How long will her anosmia last? We dont know the final time course of recovery for those with anosmia, Yan says, but it is usually from six months to a year. With long-term postviral smell loss from the flu, after six months, there is a 30 to 50 percent chance of spontaneous recovery without any treatment, she adds. There have been case reports of recovery after two years. But after that, we think the regenerative capability may be hindered. And the chances of recovery are quite slim, unfortunately.

Kantor has tried every avenue imaginable to regain his sense of smell: a course of high-dose steroids to reduce inflammation; a smell-training program with essential oils; beta-carotene supplements for nerve regeneration; acupuncture. Nothing has made a difference. Yan recommends irrigation of the sinuses with budesonide, a topical steroid shown to improve outcomesin a Stanford Universitystudy of people with postflu smell loss for more than six months. Another promising treatment Yan and others areinvestigating is platelet-rich plasma, an anti-inflammatory concoction isolated from blood that has been used to treat some types of nerve damage. But with any treatment, Yan says, the results are not amazing. Its not like youll wake up and say, Wow, I can smell again. But if you can smell soap again or enjoy the taste of some foods, thats a big gain.

There is one final worrying note about anosmia: it has beenidentified as a risk factorfor some neurodegenerative diseases. After the flu pandemic of 1919, we saw an increase in the prevalence of Parkinsons disease, Meunier says. It would be really concerning if something similar were happening here.

But Yan thinks that fear is overblown. There is certainly a link between anosmia and diseases, but we think that viral-induced anosmia is [working by] a totally different mechanism, she says. Having postviral anosmia doesnt put you at higher risk for disease. These are two completely separate phenomena. That should reassure Sawbridge and Kantorand the millions of others worldwide affected with COVID-related smell loss.

Read more about the coronavirus outbreak fromScientific Americanhere. And read coverage from our international network of magazineshere.

This article was first published atScientificAmerican.com. ScientificAmerican.com. All rights reserved. Follow Scientific American on Twitter @SciAm and @SciamBlogs. VisitScientificAmerican.comfor the latest in science, health and technology news.

Link:
Mysteries of COVID smell loss finally yield some answers - Livescience.com

Skin Stem Cells Comments Off on Mysteries of COVID smell loss finally yield some answers – Livescience.com | November 20th, 2020